Multi-projectile antibody-drug conjugate, and preparation method therefor and use thereof

Through the design of multi-warhead antibody-conjugated drugs, the extracellular lysis ability of linkers in the tumor microenvironment is used to solve the problem of drug resistance and toxicity ratio regulation of antibody-conjugated drugs in tumor treatment, and achieve the goal of multiple tumors significant suppression and optimization of safety windows.

WO2024235127A1PCT designated stage expired Publication Date: 2024-11-21MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Patent Information

Application Number
PCT/CN2024/092419
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-21
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing antibody-conjugated drugs have drug resistance problems when treating tumors, especially when tumors pump toxin molecules out of cells through PgP, ABCB1, and ABCG2 protein pumps, resulting in poor treatment effect and the toxicity ratio of dual toxin ADC is difficult to regulate. Synergies cannot be achieved.

Method used

Develop multi-warhead antibody-coupling drugs to couple with toxin linkers of different mechanisms of action through antibodies or antigen-binding fragments to form new antibody conjugates, leveraging the extracellular lysis ability of linkers in the tumor microenvironment, Overcome the endocytosis dependence and drug resistance of traditional ADCs.

Benefits of technology

It has achieved significant inhibition of tumor growth in different tumor cells, overcome tumor heterogeneity and drug resistance, and can flexibly adjust the toxin ratio to optimize drug efficacy and safety windows, simplify the preparation process and reduce costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024092419_21112024_PF_FP_ABST
    Figure CN2024092419_21112024_PF_FP_ABST
Patent Text Reader

Abstract

A multi-projectile antibody-drug conjugate as represented by formula (I), and a preparation method therefor and the use thereof in the prevention and / or treatment of diseases related to abnormal cell activity, including, but not limited to, the use in the prevention and / or treatment of tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Multi-warhead antibody-drug conjugates and their preparation method and use

[0001] This disclosure claims priority to Chinese Patent Application No. 2023105357777 filed on May 12, 2023, Chinese Patent Application No. 2023115586664 filed on November 21, 2023, and Chinese Patent Application No. 2023109434842 filed on July 28, 2023. The entire contents of the aforementioned Chinese patent applications are incorporated herein by reference. Technical Field

[0002] The present disclosure belongs to the field of medical technology and relates to multi-warhead antibody-drug conjugates, compounds, drug-linker conjugates and preparation methods thereof, as well as their use in preventing and / or treating diseases associated with abnormal cell activity, including but not limited to preventing and / or treating tumor diseases. Background Art

[0003] Great success has been achieved in improving the efficacy of cytotoxic drugs through antibody-drug conjugates (ADCs). Currently, 12 ADC drugs containing single small molecule toxins have been approved for marketing worldwide. However, tumors are highly heterogeneous, and the therapeutic effects of toxins with a single mechanism of action are limited. At the same time, tumors can also develop drug resistance during treatment, including using PgP, ABCB1, and ABCG2 protein pumps to pump toxin molecules out of cells, thereby escaping killing. Although the combined administration of two ADCs containing different toxins may overcome these problems, its administration is extremely inconvenient and patient compliance is poor. ADCs using the same antibody at the same time will antagonize each other, greatly reducing the therapeutic effect. Therefore, the development of ADCs that can overcome drug resistance is very attractive and can be used to overcome the sensitivity of heterogeneous tumor cell populations to different drugs.

[0004] To improve the efficacy of ADC drugs, patents have been published for dual-toxin ADC molecules, most of which utilize linker branching technology (creating two or more linkers on the linker) to couple with the same drug. This only serves to increase the DAR (Drug Antibody Ratio) value, but fails to achieve synergistic effects from a mechanistic perspective. Furthermore, no dual-toxin ADC has achieved clinical success. Therefore, finding multi-toxin ADCs that can achieve synergistic anti-tumor activity is difficult.

[0005] Because each toxin has different mechanisms of action, pharmacokinetic properties, effective doses, and toxicity levels, the ratio of the two toxins in most dual-toxin ADCs is 1:1 or some other fixed ratio. This ratio is clearly not optimal in terms of efficacy and toxicity, and the desired dual-toxin effect cannot be achieved. Using new conjugation technologies, the flexibly adjusted ratio of two or more toxins can achieve optimal efficacy at the same ADC dose while reducing toxicity and ensuring an optimal safety window for the ADC. This is of great significance for cancer treatment.

[0006] Existing antibody-drug conjugates (ADCs) typically bind to tumor cell surface antigens through the binding of the antibody in the ADC. The ADC then undergoes endocytosis and enters the endosome, where it is converted to the lysosome. Lysosomal hydrolases then dissociate the bioactive molecule (toxin or payload) from the ADC. The dissociated bioactive molecule then enters the cytoplasm and kills the tumor cell. The bioactive molecule that escapes from the killed tumor cell can further kill surrounding tumor cells that do not express or express low levels of the antigen (the so-called bystander effect). Alterations in any of these steps can lead to drug resistance and loss of therapeutic efficacy. These include changes in antigen expression, decreased or even loss of endocytosis, or altered endosome or lysosomal function. Therefore, it is crucial to develop an ADC that is stable in the bloodstream and capable of cleaving the toxin in the tumor microenvironment without endocytosis, thereby eliminating the toxin and achieving tumor killing. Such an ADC would overcome the various resistance mechanisms associated with traditional ADCs and would be of great clinical significance.

[0007] Summary of the Invention

[0008] In order to solve the above problems, the present invention provides a multi-warhead antibody-drug conjugate, which uses an antibody or its antigen-binding fragment as a raw material, and is coupled to an appropriate number of toxin-linkers (drug linkers) of other targets through the active site, wherein the toxin-linkers contain two or more biologically active molecules with different mechanisms of action to form a new antibody conjugate.

[0009] To this end, in the first aspect of the present disclosure, the present disclosure provides a multi-warhead antibody-drug conjugate as shown in Formula I,

[0010] or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0011] in,

[0012] T is an antibody or an antigen-binding fragment thereof;

[0013] L1, L2 and L3 are linkers, which covalently bind T and the corresponding D1, D2 and D3. L1, L2 and L3 can be the same or different;

[0014] D1, D2 and D3 are drug units, and D1, D2 and D3 may be the same or different; and when D1, D2 and D3 are the same, L1, L2 and L3 are different;

[0015] n1, n2, and n3 are each independently selected from any value between 0 and 8. When one of n1, n2, and n3 is 0, the other two are not 0.

[0016] In some embodiments, n1, n2, and n3 are each independently selected from any value between 0 and 8, and one of n1, n2, and n3 is 0, and the other two are not 0.

[0017] In some embodiments, the S atom connected to T in Formula I is not an additional external sulfur atom, but rather a -S- formed by the connection between the thiol group contained in T itself and the linker after the disulfide bond is opened.

[0018] In some embodiments, the S atoms connected to T in Formula I are all derived from disulfide bonds in antibody T.

[0019] In some embodiments, T is an antibody or antigen-binding fragment thereof, including Fab, Fab′, F(ab′)2, Fd, Fv (e.g., scFv), dAb, a complementarity determining region fragment, a non-human antibody, a humanized antibody, a chimeric antibody, a fully human antibody, a probody, a monoclonal antibody, a bispecific antibody, or a multispecific antibody.

[0020] In some embodiments, T is a non-engineered antibody.

[0021] In some embodiments, L1, L2, and L3 are linkers that covalently bind T and corresponding D1, D2, and D3, and L1, L2, and L3 may be the same or different;

[0022] D1, D2 and D3 are drug units, and D1, D2 and D3 are different.

[0023] In some embodiments, L1, L2, and L3 are linkers that covalently bind T and corresponding D1, D2, and D3, and L1, L2, and L3 are different;

[0024] D1, D2 and D3 are drug units, and D1, D2 and D3 are the same.

[0025] In some embodiments, n1 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8.

[0026] In some embodiments, n2 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8.

[0027] In some embodiments, n3 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8.

[0028] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0029] in,

[0030] T is a non-engineered antibody;

[0031] L1, L2 and L3 are linkers, which covalently bind T and the corresponding D1, D2 and D3. L1, L2 and L3 can be the same or different;

[0032] D1, D2 and D3 are drug units, and D1, D2 and D3 are different;

[0033] n1, n2, and n3 are each independently selected from any value between 0 and 8. When one of n1, n2, and n3 is 0, the other two are not 0.

[0034] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0035] in,

[0036] T is a non-engineered antibody;

[0037] L1, L2 and L3 are linkers, which covalently bind T and the corresponding D1, D2 and D3. L1, L2 and L3 are different;

[0038] D1, D2 and D3 are drug units, and D1, D2 and D3 are the same;

[0039] n1, n2, and n3 are each independently selected from any value between 0 and 8. When one of n1, n2, and n3 is 0, the other two are not 0.

[0040] In some embodiments, L1, L2, and L3 are selected from a cleavable linker and a non-cleavable linker.

[0041] In some embodiments, L1, L2, and L3 are selected from linkers that are cleavable in the tumor microenvironment.

[0042] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0043] in,

[0044] T is a non-engineered antibody;

[0045] At least one of L1, L2 and L3 is a linker that can be cleaved in the tumor microenvironment, which is covalently bound to T and the corresponding D1, D2 and D3, and L1, L2 and L3 can be the same or different;

[0046] D1, D2 and D3 are drug units, and D1, D2 and D3 are different;

[0047] n1, n2, and n3 are each independently selected from any value between 0 and 8, and when one of n1, n2, and n3 is 0, the other two are not 0;

[0048] The S atoms connected to T in Formula I are all derived from disulfide bonds in antibodies.

[0049] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0050] in,

[0051] T is a non-engineered antibody;

[0052] At least one of L1 and L2 is a linker that can be cleaved in the tumor microenvironment, which is covalently bound to T and the corresponding D1 and D2, and L1 and L2 can be the same or different;

[0053] D1 and D2 are drug units, and D1 and D2 are different;

[0054] n1 and n2 are each independently selected from any value between 0 and 8, and both n1 and n2 are not 0;

[0055] The S atoms connected to T in Formula I are all derived from disulfide bonds in antibodies.

[0056] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0057] in,

[0058] T is a non-engineered antibody;

[0059] At least one of L1 and L3 is a linker that can be cleaved in the tumor microenvironment, which is covalently bound to T and the corresponding D1 and D3, and L1 and L3 can be the same or different;

[0060] D1 and D3 are drug units, and D1 and D3 are different;

[0061] n1 and n3 are each independently selected from any value between 0 and 8, and both n1 and n3 are not 0;

[0062] The S atoms connected to T in Formula I are all derived from disulfide bonds in antibodies.

[0063] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0064] in,

[0065] T is a non-engineered antibody;

[0066] At least one of L1 and L2 is a linker that can be cleaved in the tumor microenvironment, which is covalently bound to T and the corresponding D1 and D2, and L1 and L2 can be the same or different;

[0067] D1 and D2 are drug units, and D1 and D2 are different;

[0068] n1 and n2 are each independently selected from any value between 0 and 8, and both n1 and n2 are not 0;

[0069] n3 is 0;

[0070] The S atoms connected to T in Formula I are all derived from disulfide bonds in antibodies.

[0071] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

[0072] in,

[0073] T is a non-engineered antibody;

[0074] At least one of L1 and L3 is a linker that can be cleaved in the tumor microenvironment, which is covalently bound to T and the corresponding D1 and D3, and L1 and L3 can be the same or different;

[0075] D1 and D3 are drug units, and D1 and D3 are different;

[0076] n1 and n3 are each independently selected from any value between 0 and 8, and both n1 and n3 are not 0;

[0077] n2 is 0;

[0078] The S atoms connected to T in Formula I are all derived from disulfide bonds in antibodies.

[0079] In some embodiments, the linker comprises an amino acid residue or a short peptide consisting of 2-10 amino acid residues. Preferably, the linker comprises a dipeptide, a tripeptide or a tetrapeptide.

[0080] In some embodiments, the amino acid residue is selected from Val, Ala, Gly, Cit, Arg, Phe, Lys, Asn, and amino acid residues thereof modified by substitution.

[0081] In some embodiments, the dipeptide is selected from Val-Cit, Val-Ala, Ala-Ala, Val-Lys, and the above dipeptides modified by substitution.

[0082] In some embodiments, the tripeptide is selected from Ala-Ala-Ala, Ala-Ala-Asn, Val-Lys-Gly, Ala-Lys-Gly, Gly-Lys-Gly, Val-Lys-Ala, Ala-Lys-Ala, Gly-Lys-Ala, and substitution-modified versions of the above tripeptides.

[0083] In some embodiments, the tetrapeptide is selected from Gly-Gly-Phe-Gly and Gly-Gly-Val-Ala and substitution-modified tetrapeptides thereof.

[0084] In some embodiments, the linker is selected from the following structures

[0085] in,

[0086] La is a linker unit that covalently binds T and Lb;

[0087] Lb is a linking unit that covalently binds La and Lc;

[0088] Lc is an amino acid residue or a polypeptide consisting of 2-10 amino acid residues, The amino acid residue is selected from natural amino acid residues, non-natural amino acid residues, substituted and modified amino acid residues or stereoisomers thereof; and is covalently bound to Lb and Ld;

[0089] Ld is a direct bond or a spacer unit that covalently binds Lc and the Drug unit.

[0090] In some embodiments, La is selected from heteroaryl, partially saturated heteroaryl, heteroarylbiaryl, heteroarylbiheteroaryl, heterocyclyl, oxo heterocyclyl, maleimide, cycloalkenyl, alkylamide, cycloalkylcarbonyl, heterocycloalkylcarbonyl, alkenylamide, where R p Selected from C1-6 alkyl, -(CH2CH2O) q H, -(CH2CH2O) q -C1-6 alkyl, q is selected from any integer between 0 and 30, the 1-position is connected to the S atom, and the 2-position is connected to Lb.

[0091] In some embodiments, L a Selected from Position 1 is connected to the S atom, and position 2 is connected to Lb.

[0092] In some embodiments, La is selected from Position 1 is connected to the S atom, and position 2 is connected to Lb.

[0093] In some embodiments, La is selected from Position 1 is connected to the S atom, and position 2 is connected to Lb.

[0094] In some embodiments, La is selected from Position 1 is connected to the S atom, and position 2 is connected to Lb.

[0095] In some embodiments, Lb is Position 1 is connected to La, position 2 is connected to Lc;

[0096] in,

[0097] W is selected from -CR x1 R x2 -,

[0098] R x1 、R x2 Each is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl;

[0099] Or, R x1 With R x2 Together with the carbon atoms to which they are attached, they form a 3-6 membered carbocyclic ring or a 3-6 membered heterocyclic ring;

[0100] Y is independently selected from -O-, -CH2-, -OCH2CH2-, -CH2CH2O-, or any combination of one or more of the above groups;

[0101] X is selected from -CR x3 R x4 -and-NR x5 -;

[0102] R x3 、R x4 、R x5 Each is independently selected from hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl;

[0103] Or, R x3 With R x4 Together with the carbon atoms to which they are attached, they form a 3-6 membered carbocyclic ring or a 3-6 membered heterocyclic ring;

[0104] m1 and m2 are each independently selected from 0, 1, 2, 3, 4, and 5;

[0105] m is selected from any integer between 0 and 10; preferably, m is selected from 1, 2, 3, 4, 5, 6, 7, and 8.

[0106] In some embodiments, W is selected from -CH2-.

[0107] In some embodiments, X is selected from -CR x3 R x4 -, R x3 、R x4 are each independently selected from hydrogen or methyl.

[0108] In some embodiments, Lb is

[0109] In some embodiments, Lb is selected from Position 1 is connected to La, and position 2 is connected to Lc.

[0110] In some embodiments, Lb is selected from Position 1 is connected to La, and position 2 is connected to Lc.

[0111] In some embodiments, Lb is selected from Position 1 is connected to La, and position 2 is connected to Lc.

[0112] In some embodiments, Lb is selected from Position 1 is connected to La, and position 2 is connected to Lc.

[0113] In some embodiments, Lc is an amino acid residue or a short peptide consisting of 2-10 amino acid residues. The amino acid residue is selected from natural amino acid residues, non-natural amino acid residues, substituted or modified amino acid residues, or stereoisomers thereof. Preferably, it is a dipeptide, tripeptide, or tetrapeptide.

[0114] In some embodiments, Lc is selected from Val-Cit, Val-Ala, Val-Lys, Ala-Ala-Ala, Ala-Ala-Asn, Val-Lys-Gly, Gly-Gly-Phe-Gly, and the above dipeptides, tripeptides, or tetrapeptides modified by substitution.

[0115] In some embodiments, Lc is selected from

[0116] Wherein, R1 and R2 are each independently selected from hydrogen, C1-6 alkyl (such as methyl, ethyl, propyl), C3-6 cycloalkyl (such as cyclopropyl); preferably, R1 and R2 are both methyl, ethyl or propyl, position 1 is connected to Lb, and position 2 is connected to Ld.

[0117] In some embodiments, Lc is selected from

[0118] Wherein, R1 and R2 are each independently selected from hydrogen, C1-6 alkyl (such as methyl, ethyl, propyl), C3-6 cycloalkyl (such as cyclopropyl); preferably, R1 and R2 are both methyl, ethyl or propyl, position 1 is connected to Lb, and position 2 is connected to Ld.

[0119] In some embodiments, Lc is a fragment that can be cleaved in the tumor microenvironment, preferably Bit 1 is connected to Lb, and bit 2 is connected to Ld.

[0120] In some embodiments, Lc is selected from Bit 1 is connected to Lb, and bit 2 is connected to Ld.

[0121] In some embodiments, Lc is selected from Bit 1 is connected to Lb, and bit 2 is connected to Ld.

[0122] In some embodiments, Lc is a fragment that can be cleaved in the tumor microenvironment, preferably Bit 1 is connected to Lb, and bit 2 is connected to Ld.

[0123] In some embodiments, Ld is selected from a direct bond, Position 1 is connected to Lc, and position 2 is connected to the drug unit.

[0124] In some embodiments, Ld is selected from a direct bond, Position 1 is connected to Lc, and position 2 is connected to the drug unit.

[0125] In some embodiments, L1, L2, and L3 are each independently selected from the following structures:

[0126] Among them, position 1 is connected to the S atom, and position 2 is connected to the drug unit; R1 and R2 are each independently selected from hydrogen, C1-6 alkyl (such as methyl, ethyl, propyl), C3-6 cycloalkyl (such as cyclopropyl); preferably, R1 and R2 are both methyl, ethyl or propyl.

[0127] In some preferred embodiments, L1, L2 and L3 are each independently selected from the following structures:

[0128] wherein position 1 is connected to the S atom, and position 2 is connected to the drug unit; R1 and R2 are each independently selected from H, C1-6 alkyl (e.g., methyl, ethyl, propyl), or C3-6 cycloalkyl (e.g., cyclopropyl); preferably, R1 and R2 are both methyl, ethyl, or propyl. In some preferred embodiments, L1, L2, and L3 are each independently selected from the following structures:

[0129] Among them, position 1 is connected to the S atom, and position 2 is connected to the drug unit.

[0130] In some embodiments, L1 is Preferably

[0131] In some embodiments, L2 is Preferably

[0132] In some embodiments, L3 is Preferably

[0133] In some embodiments, D1, D2, and D3 are biologically active molecular fragments.

[0134] In some embodiments, the biologically active molecule is selected from, but is not limited to, radioisotopes such as At 211, I 131, I 125, Y 90, Re 186, Re 188, Sm 153, Bi 212, P 32, Pb 212, and radioisotopes of Lu; metal complexes such as metal platinum complexes (e.g., oxaliplatin), metal gold complexes; glycopeptide antibiotics such as bleomycin or bleomycin; glucocorticoids such as prednisone, prednisolone, or dexamethasone; calcineurin inhibitors such as cyclosporine, tacrolimus; alkylating agents such as nitrogen mustard, chlorambucil, cyclophosphamide, busulfan, mitomycin C, or melphalan; DNA topoisomerase inhibitors, including topoisomerase I Inhibitors, such as camptothecin derivatives; topoisomerase II inhibitors, such as actinomycin D, doxorubicin, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin, nemorubicin, PNU-159682, or etoposide; drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine, nelarabine, pyrrolobenzodiazepine dimers (PBD), dukamycin or calicheamicin and their derivatives; drugs acting on structural proteins, including microtubule inhibitors, such as vinca alkaloids, vincristine, eribulin and its derivatives, vinblastine, Tubulysins, maytansine derivatives, MMAE / MMAF and its derivatives, paclitaxel, epothilone, docetaxel or cabazitaxel, combretastatin and its derivatives; tumor signaling pathway inhibitors, such as serine / threonine kinase inhibitors, tyrosine kinase inhibitors, aspartate kinase inhibitors or histidine kinase inhibitors; proteasome inhibitors, such as bortezomib, ixazomib, carfilzomib; protease inhibitors, such as carbamacin A or carbamazine. The invention also includes but is not limited to: mycin B; histone deacetylase inhibitors; tumor angiogenesis inhibitors; cell cycle protein inhibitors; nucleic acid drugs, such as antisense oligonucleotides (ASO), small interfering RNA (siRNA), microRNA, nucleic acid aptamers (Aptamer), messenger RNA (mRNA); immunomodulators, such as thymosin, levamisole, Toll-like receptor modulators, STING modulators; toxins, such as small molecule toxins: amatoxin or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof; steroidal saponins; thailanstatin and its analogs, such as thailanstatin A; BCL-x1 / BCL2 inhibitors; and other active substances that inhibit tumor cell growth and promote tumor cell apoptosis or necrosis.

[0135] In some embodiments, D1, D2 and D3 are each independently selected from, but not limited to, microtubule inhibitors, such as MMAE / MMAF and its derivatives, eribulin and its derivatives, maytansine derivatives; topoisomerase inhibitors, such as camptothecin derivatives; drugs that interfere with DNA synthesis, such as dukamycin or calicheamicin and its derivatives.

[0136] In some embodiments, D1, D2, and D3 are each independently selected from MMAE / MMAF and its derivatives, eribulin and its derivatives, camptothecin derivatives, ducathiamycin, or calicheamicin and its derivatives.

[0137] In some preferred embodiments, the camptothecin derivatives are selected from the following structures:

[0138] In some preferred embodiments, the camptothecin derivatives are selected from the following structures:

[0139] In some embodiments, the camptothecin derivative is

[0140] In some embodiments, D1 is a camptothecin derivative.

[0141] In some embodiments, the eribulin derivative is selected from the following structures:

[0142] In some preferred embodiments, the eribulin derivative is selected from the following structures:

[0143] In some embodiments, the ducathiamycin or calicheamicin and derivatives thereof are selected from the following structures:

[0144] In some preferred embodiments, the ducathiamycin or calicheamicin and its derivatives are selected from the following structures:

[0145] In some embodiments, D2 is eribulin and its derivatives, ducathiamycin, or calicheamicin and its derivatives.

[0146] In some embodiments, D2 is eribulin and its derivatives.

[0147] In some embodiments, D2 is ducarmycin or calicheamicin and derivatives thereof.

[0148] In some embodiments, D2 is ducathiamycin and its derivatives.

[0149] In some embodiments, D2 is calicheamicin and its derivatives.

[0150] In some embodiments, the MMAE / MMAF and its derivatives are selected from the following structures:

[0151] In some preferred embodiments, the MMAE / MMAF and its derivatives are selected from the following structures:

[0152] In some preferred embodiments, the MMAE / MMAF and its derivatives are

[0153] In some embodiments, D3 is MMAE / MMAF and its derivatives.

[0154] In some embodiments, -L1-D1, -L2-D2, and -L3-D3 are selected from any combination of L1, L2, L3 and D1, D2, and D3 described in any embodiment of the present disclosure.

[0155] In some embodiments, -L1-D1 is selected from the following structural fragments:

[0156] In some embodiments, -L1-D1 is selected from the following structural fragments:

[0157] In some preferred embodiments, -L1-D1 is selected from the following structural fragments:

[0158] In some preferred embodiments, -L1-D1 is In some embodiments, -L2-D2 is selected from the following structural fragments:

[0159] In some embodiments, -L2-D2 is selected from the following structural fragments:

[0160] In some preferred embodiments, -L2-D2 is preferably

[0161] In some preferred embodiments, -L2-D2 is selected from the following structural fragments:

[0162] In some embodiments, -L3-D3 is selected from the following structural fragments:

[0163] In some embodiments, -L3-D3 is selected from the following structural fragments:

[0164] In some preferred embodiments, -L3-D3 is selected from the following structural fragments:

[0165] In some preferred embodiments, -L3-D3 is

[0166] In some embodiments, T is selected from antibodies that bind to the following targets: epidermal growth factor, integrin α5β6, integrin α4β7, 0772P, 5T4, ACTA2, ADGRE1, AGS-16, AIF1, AKR1C1, AKR1C2, ANGPTL4, ApoE, ASLG659, BAFF-R, BMPR1B, BNIP3, Brevican, C1QA, C1QB, CA6, pCAD, P-cadh erin, CADM1, CCL5, CCR5, CD11b, CD11c, CD19, CD20, CD21, CD22, CD30, CD33, CD37, CD40, CD45 (PTPRC) , CD49D(ITGA4), CD56, CD66e, CD70, CD72, CD74, CD79a, CD80, CD138, CD223, CDCP1, CDH11, Claudin18.2. COL6A3, COL7A1, CRIPTO, CSF1R, CTGF, CTSD, CTSS, CXCL10, CXCL11, CXCR5, DDIT4, DLL3, DLL4, DR5, E16, EFNA4, B7H3, EGFR, EGFRvIII, EGLN, EGLN3, EMR2, Endothelin receoptor, ENPP3, EpCAM, EphB2R, ETBR, FGF2, FGFR2, FcRH1, FcRH2, GEDA, GPNMB, GZMB, Her2, Her3, HLA-DOB, HM OX1, IFNG, IFI6, IGF-1R, IGFBP3, IL10RA1, IL20Rα, IL-6, IRTA2, KISS1R, KRT33A, LOX, LRRC15, LUM, LY6E, LY64, L Y86, LYPD3, MCPT8, MDP, Mesothelin, c-Met, MFI2, MMP10, MMP14, MMP16, MPF, MSG783, MS4A7, MUC1, MUC16, NaPi2 b, NaPi3b, NCA, Nectin4, NOG, P2X5, PD-L1, PDK1, PDGFRA, PFKFB3, PGF, PGK1, PIK3AP1, PIK3CD, PLOD2, PSCA, PSCA hlg, PSMA, RNF43, ROR1, Sema5b, SERPINE1, SLC39A6, SLITRK6, SLTRK6, STAT1, STC2, STEAP1, STEAP2, TCF4, TENB2, TGF, TGFBR1, TGFB2, Tissue factor, TNFRSF21, TNFSF9, Trop-2, TrpM4, Tyro7, UPK1B, VEGFA and WNT5A. .

[0167] In some embodiments, T is an anti-Her2 antibody or an antigen-binding fragment thereof, an anti-B7H3 antibody or an antigen-binding fragment thereof, or an anti-Trop-2 antibody or an antigen-binding fragment thereof.

[0168] In some preferred embodiments, T is an anti-Her 2 antibody, such as trastuzumab or pertuzumab, preferably trastuzumab.

[0169] In some preferred embodiments, T is an anti-B7H3 antibody, such as 1D1, 1D1-01, 2E3, 2E3-02 antibodies, enoblituzumab, mirzotamab, or omburtamab.

[0170] In some embodiments, T is an anti-Trop-2 antibody, such as Sacituzumab.

[0171] In some preferred embodiments, the dual-warhead antibody conjugate of Formula I, or a stereoisomer of the dual-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof;

[0172] in,

[0173] n1 and n2 are each independently selected from any value between 1 and 8, and n3 is 0;

[0174] D1 is a camptothecin derivative;

[0175] D2 is eribulin and its derivatives;

[0176] The definitions of T, L1, and L2 are as described in any embodiment of the present disclosure.

[0177] Preferably, at least one of L1 and L2 is a linker that can be cleaved in the tumor microenvironment.

[0178] In some preferred embodiments, the dual-warhead antibody conjugate of Formula I, or a stereoisomer of the dual-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof;

[0179] in,

[0180] n1 and n2 are each independently selected from any value between 1 and 8, and n3 is 0;

[0181] D1 is a camptothecin derivative;

[0182] D2 is ducarcin or calicheamicin and its derivatives;

[0183] The definitions of T, L1, and L2 are as described in any embodiment of the present disclosure.

[0184] Preferably, at least one of L1 and L2 is a linker that can be cleaved in the tumor microenvironment.

[0185] In some preferred embodiments, n1+n2 is approximately equal to 8, and n1 / n2 is approximately equal to 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5.

[0186] In some preferred embodiments, n1+n2 is approximately equal to 7-8, for example, approximately equal to 8; n1 / n2 is approximately equal to 1-8, for example, approximately equal to 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7 or 7.5.

[0187] In some preferred embodiments, n1+n2 is approximately equal to 4, and n1 / n2 is approximately equal to 1, 1.5, 2, 2.5, 3, 3.5 or 4.

[0188] In some preferred embodiments, the dual-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the dual-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof;

[0189] in,

[0190] n1 and n3 are each independently selected from any value between 1 and 8, and n2 is 0;

[0191] D1 is a camptothecin derivative;

[0192] D3 is MMAE / MMAF and its derivatives;

[0193] The definitions of T, L1, and L3 are as described in any embodiment of the present disclosure.

[0194] Preferably, at least one of L1 and L3 is a linker that can be cleaved in the tumor microenvironment.

[0195] In some preferred embodiments, n1+n3 is approximately equal to 8, and n1 / n3 is approximately equal to 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5.

[0196] In some preferred embodiments, n1+n3 is approximately equal to 7 to 8, for example, approximately equal to 8; n1 / n3 is approximately equal to 1 to 8, for example, approximately equal to 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7 or 7.5; n1 / n3 is preferably approximately equal to 2.5 to 3.5, for example, approximately equal to 3.

[0197] In some preferred embodiments, n1+n3 is approximately equal to 4, and n1 / n2 is approximately equal to 1, 1.5, 2, 2.5, 3, 3.5 or 4.

[0198] In some preferred embodiments, the dual-warhead antibody-drug conjugate of Formula I, or a stereoisomer of the dual-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof;

[0199] in,

[0200] n2 and n3 are each independently selected from any value between 1 and 8, and n1 is 0;

[0201] D2 is eribulin and its derivatives;

[0202] D3 is MMAE / MMAF and its derivatives;

[0203] The definitions of T, L2, and L3 are as described in any embodiment of the present disclosure.

[0204] In some preferred embodiments, n2+n3 is approximately equal to 8, and n3 / n2 is approximately equal to 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5.

[0205] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I is selected from:

[0206] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I is selected from: Wherein T is an anti-Her2 antibody, such as trastuzumab or pertuzumab, preferably trastuzumab.

[0207] In some embodiments, the multi-warhead antibody-drug conjugate of Formula I is selected from:

[0208] Wherein T is an anti-B7H3 antibody, such as 1D1, 1D1-01, 2E3, 2E3-02 antibodies, enoblituzumab, mirzotamab, omburtamab.

[0209] The present disclosure also provides a method for preparing the multi-warhead antibody-drug conjugate of Formula I or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Surprisingly, it was found that the preparation method of the present disclosure can flexibly adjust the ratio of two or more toxins.

[0210] The method comprises: conducting a coupling reaction in a suitable solvent between an antibody T(SH)n with opened interchain disulfide bonds and a mixture of Lg-L1-D1, Lg-L2-D2, and Lg-L3-D3 in a determined ratio;

[0211] in:

[0212] When the linkers of L1, L2, and L3 contain When Lg-L1, Lg-L2, Lg-L3 contain

[0213] When the linkers of L1, L2, and L3 contain When Lg is a leaving group when reacting with T(SH)n; preferably, Lg is selected from halogen, sulfone, tertiary amine salt (Me3N+, Et3N+), diazonium salt, -OMs, MeSO2-, CF3SO3-; more preferably, Lg is selected from F, MeSO2-;

[0214] The definitions of L1, D1, L2, D2, L3, D3, n1, n2, and n3 are as described in any embodiment of the present disclosure.

[0215] In some embodiments, the coupling reaction is carried out in water and / or an organic solvent.

[0216] In some embodiments, the organic solvent is selected from N,N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, nitriles (such as acetonitrile), alcohols (such as methanol, ethanol) or any combination thereof.

[0217] In some embodiments, the method further comprises the step of purifying the coupling product.

[0218] In some embodiments, the coupled product is purified by chromatography.

[0219] In some embodiments, the chromatography method comprises one or more of ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography, or affinity chromatography.

[0220] In some embodiments, the method comprises: conducting a coupling reaction between an antibody T(SH)n with opened interchain disulfide bonds and a mixture of Lg-L1-D1 and Lg-L2-D2 in a determined ratio in a suitable solvent; the definitions of L1, D1, L2, D2, Lg, and T are as described in any embodiment of the present disclosure.

[0221] In some embodiments, the determined ratio of Lg-L1-D1 and Lg-L2-D2 is 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5; preferably 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5.

[0222] In some embodiments, the method comprises: opening the interchain disulfide bonds of antibody T(SH)n, and sequentially or simultaneously adding Lg-L1-D1 and Lg-L2-D2 in a determined ratio in a suitable solvent for coupling reaction.

[0223] In some embodiments, the method comprises: conducting a coupling reaction between an antibody T(SH)n with opened interchain disulfide bonds and a mixture of Lg-L1-D1 and Lg-L3-D3 in a determined ratio in a suitable solvent; the definitions of L1, D1, L3, D3, Lg, and T are as described in any embodiment of the present disclosure.

[0224] In some embodiments, the determined ratio of Lg-L1-D1 and Lg-L3-D3 is 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5; preferably 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5.

[0225] In some embodiments, the method comprises: opening the interchain disulfide bonds of the antibody T(SH)n, and sequentially or simultaneously adding Lg-L1-D1 and Lg-L3-D3 in a determined ratio in a suitable solvent for coupling reaction.

[0226] In some embodiments, Lg-L1-D1, Lg-L2-D2, Lg-L3-D3 are selected from the following compounds:

[0227] In some embodiments, Lg-L1-D1 is selected from the following compounds,

[0228] In some embodiments, Lg-L1-D1 is selected from the following compounds,

[0229] In some embodiments, Lg-L1-D1 is selected from the following compounds,

[0230] In some embodiments, the Lg-L1-D1 is

[0231] In some embodiments, Lg-L2-D2 is selected from the following compounds,

[0232] In some embodiments, Lg-L2-D2 is selected from the following compounds,

[0233] In some embodiments, Lg-L2-D2 is

[0234] In some embodiments, Lg-L2-D2 is

[0235] In some embodiments, Lg-L3-D3 is selected from the following compounds,

[0236] In some embodiments, Lg-L3-D3 is selected from the following compounds,

[0237] In some embodiments, Lg-L3-D3 is selected from the following compounds,

[0238] In some embodiments, Lg-L3-D3 is

[0239] The present disclosure also provides a drug-linker conjugate, or a stereoisomer of the drug-linker conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, the structure of which is as follows:

[0240] The present disclosure also provides a method for preparing drug-linker conjugates Lg-L1-D1, Lg-L2-D2, and Lg-L3-D3, comprising: reacting Lg-L1-Lg1, Lg-L2-Lg2, and Lg-L3-Lg3 with corresponding D1, D2, and D3;

[0241] For example:

[0242] Lg-L1-Lg1+D1→Lg-L1-D1;

[0243] Lg-L2-Lg2+D2→Lg-L2-D2;

[0244] Lg-L3-Lg3+D3→Lg-L3-D3;

[0245] Wherein, Lg, L1, D1, L2, D2, L3, D3 are defined as described in any embodiment of the present disclosure, Lg1, Lg2, Lg3 are each independently selected from hydroxyl, halogen, activated hydroxyl, such as hydroxyl, chlorine, bromine,

[0246] Specifically:

[0247] Compound 12-9 of the general formula undergoes a condensation reaction with eribulin to obtain the target compound DL012. Drug-linker conjugates with various structures, such as Lg-L1-D1, Lg-L2-D2, and Lg-L3-D3, can be obtained by condensing analogs of 12-9 with different drug molecules.

[0248] The present disclosure provides linkers Lg-L1-Lg1, Lg-L2-Lg2, and Lg-L3-Lg3. The present disclosure also provides methods for preparing Lg-L1-Lg1, Lg-L2-Lg2, and Lg-L3-Lg3, wherein Lg, L1, L2, L3, Lg1, Lg2, and Lg3 are as defined in any embodiment of the present disclosure.

[0249] Specifically:

[0250] Compound 12-1 of the general formula is subjected to substitution, coupling, hydrolysis, and oxidation to obtain compound 12-5 of the general formula, which is then subjected to condensation reactions to obtain compound 12-9 of the general formula. Analogs of 12-5 can be obtained through similar substitution, coupling, hydrolysis, and oxidation reactions, and further condensation reactions can yield various structures of Lg-L1-Lg1, Lg-L2-Lg2, and Lg-L3-Lg3.

[0251] The present disclosure provides drugs D1, D2, and D3. The present disclosure also provides methods for preparing drugs D1, D2, and D3, wherein D1, D2, and D3 are as defined in any of the embodiments of the present disclosure, for example, MMAE / MMAF and its derivatives, eribulin and its derivatives, maytansine derivatives, camptothecin derivatives, etc., and can be produced from a parent compound in one or more chemical reaction steps.

[0252] Specifically:

[0253] Compound 6-13 of the general formula is condensed with N-methylhydroxyethylamine to obtain target compound 6-14. MMAE / MMAF, eribulin, camptothecin, etc. can be condensed with different fragments to obtain various structures of D1, D2, and D3.

[0254] The present disclosure provides use of the aforementioned drug, or a stereoisomer of the drug, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof for preparing an antibody-drug conjugate.

[0255] The present disclosure provides use of the aforementioned drug, or a stereoisomer of the drug, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof for preparing a multi-warhead antibody-drug conjugate.

[0256] The present disclosure provides the use of the aforementioned drug-linker conjugate, or a stereoisomer of the drug-linker conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof for preparing an antibody-drug conjugate.

[0257] The present disclosure provides the use of the aforementioned drug-linker conjugate, or a stereoisomer of the drug-linker conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof for preparing a multi-warhead antibody-drug conjugate.

[0258] The present disclosure provides a pharmaceutical composition comprising the aforementioned multi-warhead antibody-drug conjugate, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; and optionally one or more pharmaceutical excipients.

[0259] The present disclosure provides the aforementioned multi-warhead antibody-drug conjugate, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; or use of the aforementioned pharmaceutical composition in the preparation of a drug for treating and / or preventing diseases associated with abnormal cell activity (e.g., cancer diseases).

[0260] The present disclosure provides the aforementioned multi-warhead antibody-drug conjugate, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; or the aforementioned pharmaceutical composition, which is used to treat and / or prevent diseases associated with abnormal cell activity (e.g., cancer diseases).

[0261] The present disclosure provides a method for preventing and / or treating diseases associated with abnormal cell activity (e.g., cancer), comprising: administering to an individual in need thereof a preventive and / or therapeutically effective amount of the aforementioned multi-warhead antibody-drug conjugate, or a stereoisomer of the multi-warhead antibody-drug conjugate, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; or the aforementioned pharmaceutical composition.

[0262] In some embodiments, the cancer disease is a solid tumor and / or a hematological tumor.

[0263] In some embodiments, the cancer disease is selected from esophageal cancer (e.g., esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial carcinoma, non-Hodgkin's lymphoma, central nervous system tumor (e.g., glioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer; preferably selected from gastric cancer, non-small cell lung cancer, breast cancer and breast adenocarcinoma.

[0264] In some specific embodiments, the cancer disease is selected from tumors with high HER2 expression or low HER2 expression; the tumor with high HER2 expression is preferably breast adenocarcinoma, and the tumor with low HER2 expression is preferably gastric cancer and / or breast cancer.

[0265] In some specific embodiments, the cancer disease is selected from drug-resistant tumors, and the drug resistance includes single toxin ADC resistance and single toxin ADC combination resistance; the drug-resistant tumor is selected from esophageal cancer (such as esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (such as small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial carcinoma, non-Hodgkin's lymphoma, central nervous system tumors (such as glioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer; preferably, the ABCB1 or ABCG2 transporter is overexpressed in the drug-resistant tumor; the drug-resistant tumor is preferably gastric cancer resistant to Enhertu.

[0266] definition:

[0267] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of this disclosure, definitions and explanations of relevant terms are provided below.

[0268] As used herein, the term "pharmaceutically acceptable salt" is exemplified by organic acid addition salts formed from organic acids that form pharmaceutically acceptable anions, including but not limited to formates, acetates, propionates, benzoates, maleates, fumarates, succinates, tartrates, citrates, ascorbates, α-ketoglutarate, α-glycerophosphates, alkylsulfonates, or arylsulfonates; preferably, the alkylsulfonate is methylsulfonate or ethylsulfonate; and the arylsulfonate is benzenesulfonate or p-toluenesulfonate. Suitable inorganic salts may also be formed, including but not limited to hydrochlorides, hydrobromides, hydroiodides, nitrates, bicarbonates, carbonates, sulfates, or phosphates.

[0269] Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example, by reacting a sufficient amount of a basic compound with a suitable acid affording a pharmaceutically acceptable anion.

[0270] As used in this disclosure, the term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In compounds with one or more (e.g., one, two, three, or four) asymmetric centers, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers can be produced. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. It is understood that the scope of this disclosure encompasses all such isomers or mixtures thereof in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%).

[0271] Solid lines (-), solid wedges, or dashed wedges may be used in this disclosure to depict carbon-carbon bonds of the compounds of the present invention. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomers exist. When present in a racemic mixture, solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to exist in the form of stereoisomers (which include cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof). The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).

[0272] The compounds of the present disclosure may exist in the form of solvates (preferably hydrates), wherein the compounds of the present disclosure contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of the polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.

[0273] The present disclosure further includes within its scope prodrugs of the compounds of the present invention. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compound in vivo. Therefore, in these cases, the term "administering" as used in the methods of treatment of the present disclosure should include treating various diseases or conditions with one or more prodrug forms of the claimed compounds, but the prodrug forms are converted into the aforementioned compounds in vivo after administration to the individual. For example, conventional methods for selecting and preparing suitable prodrug derivatives are described in "Design of Prodrug," ed. H. Bundgaard, Elsevier, 1985.

[0274] For the purposes of this disclosure, pharmaceutical excipients refer to excipients and additives used in the production of pharmaceuticals and the preparation of prescriptions. These substances, in addition to the active ingredients, have been reasonably evaluated for safety and are included in pharmaceutical preparations. In addition to providing shape, acting as carriers, and improving stability, pharmaceutical excipients also have important functions such as solubilization, dissolution enhancement, and sustained-release control. They are important components that may affect the quality, safety, and efficacy of drugs. Based on their source, they can be categorized as natural, semi-synthetic, and fully synthetic. According to their functions and uses, they can be divided into: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoaming agents, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids, release retardants, etc. According to their route of administration, they can be divided into oral, parenteral, mucosal, transdermal or topical administration, nasal or oral inhalation administration, and ocular administration, etc. The same pharmaceutical excipient can be used in pharmaceutical preparations for different routes of administration and have different functions and uses.

[0275] The pharmaceutical composition can be prepared into various suitable dosage forms according to the route of administration, such as tablets, capsules, granules, oral solutions, oral suspensions, oral emulsions, powders, tinctures, syrups, injections, suppositories, ointments, creams, pastes, ophthalmic preparations, pills, implants, aerosols, powder sprays, sprays, etc. The pharmaceutical composition or suitable dosage form can contain 0.01 mg to 1000 mg of the compound of the present disclosure or a pharmaceutically acceptable salt or conjugate thereof, preferably 0.1 mg to 800 mg, preferably 0.5-500 mg, preferably 0.5 to 350 mg, and particularly preferably 1-250 mg.

[0276] The pharmaceutical composition can be administered in the form of an injection, including an injection solution, sterile powder for injection, and concentrated solution for injection. Usable carriers and solvents include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils, such as monoglycerides or diglycerides, can also be used as solvents or suspending media. The pharmaceutical composition can be administered in the form of an infusion.

[0277] As used herein, the term "treat" generally refers to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in terms of completely or partially preventing a disease or its symptoms; and / or therapeutic, in terms of partially or completely stabilizing or curing a disease and / or causing side effects due to the disease. As used herein, "treat" encompasses any treatment of a disease in a patient, including: (a) preventing the disease or symptoms from occurring in a patient who is susceptible to the disease or symptoms but has not yet been diagnosed with the disease; (b) suppressing the symptoms of a disease, i.e., preventing its development; or (c) alleviating the symptoms of a disease, i.e., causing the disease or symptoms to regress.

[0278] In the present disclosure, the term "individual" includes humans and non-human animals. Exemplary human individuals include human individuals suffering from a disease (e.g., a disease described in the present disclosure) (referred to as a patient) or a normal individual. The term "non-human animal" in the present disclosure includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0279] As used herein, the term "effective dose" refers to an amount of a multi-targeted ligand-drug conjugate, drug-linker conjugate, compound, or composition that, when administered, will alleviate to some extent one or more symptoms of the condition being treated.

[0280] As used herein, the term "multi-warhead antibody-drug conjugate" refers to an antibody-drug conjugate (ADC) molecule that carries two or three different toxin molecules (payloads). Such dual- or triple-warhead ADCs can kill tumor cells through the mechanisms of action of different toxins (payloads), thereby increasing the anti-tumor efficacy of the dual- or triple-warhead ADC and reducing the development of drug resistance.

[0281] In the present disclosure, the term "drug" refers to a substance that inhibits or prevents the function of cells and / or causes cell death or destruction.

[0282] Unless otherwise indicated in this disclosure, a "derivative" of a compound, as used herein, refers to a substance that has a similar chemical structure to the compound but also contains at least one chemical group not present in the compound and / or lacks at least one chemical group present in the compound. The compound to which the derivative is compared is referred to as the "parent" compound. Typically, a "derivative" can be produced from the parent compound in one or more chemical reaction steps.

[0283] In the present disclosure, the term "linker" refers to a fragment that connects a biologically active compound fragment (drug molecule, drug unit) to a pharmacokinetics regulating fragment (antibody or antigen-binding fragment thereof).

[0284] In the present disclosure, the term "linker that can be cleaved in the tumor microenvironment" means that the linker has the ability to be cleaved in the tumor microenvironment without the need for cellular endocytosis, thereby dissociating and shedding the toxin in the tumor microenvironment, for example

[0285] In the present disclosure, the term "pharmacokinetic regulatory fragment" is interpreted in the broadest sense, referring to a molecule capable of regulating the pharmacokinetic properties, such as increasing tumor exposure and prolonging the duration of drug action. Such pharmacokinetic regulatory fragments include intact monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies) formed by at least two intact antibodies, ligands of tumor cell surface receptors, including small molecule ligands, peptides of C3-40 amino acid residues, as long as they have the desired biological activity, polyethylene glycol, and long-chain aliphatic hydrocarbons.

[0286] In the present disclosure, the term "short peptide" refers to a peptide consisting of 2 to 10 amino acids, also known as an oligopeptide or oligomeric peptide.

[0287] In this disclosure, unless otherwise explicitly stated, the descriptions “each independently selected from” and “each independently selected from” used throughout this disclosure are interchangeable and should be understood in a broad sense. They can mean that in different groups, the specific options expressed by the same or different symbols do not affect each other, or that in the same group, the specific options expressed by the same or different symbols do not affect each other.

[0288] In the present disclosure, those skilled in the art will understand that the "-S-" (S atom) in the general formula refers to the linker being connected to the sulfhydryl group contained in T (such as an antibody) after the disulfide bond is opened (for example, the disulfide bond can be opened by reducing the disulfide bond with the reducing agent TCEP to generate a sulfhydryl group -SH). In other words, the -S- between the linker and T is not an additional external sulfur atom.

[0289] In the present disclosure, regarding "connected to an S atom", it can be understood by those skilled in the art that the linker is connected to the sulfhydryl group contained in T (such as an antibody) after the disulfide bond is opened (for example, the disulfide bond can be opened by reducing the disulfide bond with the reducing agent TCEP to generate a sulfhydryl group -SH). In other words, the -S- between the linker and T is not an additional external sulfur atom. For example, the -S- is not an additional external sulfur atom, but the sulfhydryl group contained in T after the disulfide bond is opened and connected to the linker (for example ) are connected to form -S-.

[0290] Throughout this specification, substituents of the disclosed compounds are disclosed by group class or range. It is specifically noted that the disclosure includes every independent subcombination of the individual members of these group classes and ranges. For example, the term "C1-6 alkyl" specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.

[0291] In the present disclosure, the terms "comprises," "comprising," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.

[0292] In this disclosure, the term "about" generally refers to variations within a range of 0.5%-20% above or below a specified value, for example, 0.5%, 1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5% or 10.0% above or below a specified value.

[0293] In the present disclosure, the term "C1-6 alkyl" refers to a straight-chain or branched alkyl group containing 1 to 6 carbon atoms, including, for example, "C1-3 alkyl" or "C1-4 alkyl", methyl, ethyl, etc. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0294] In the present disclosure, the term "C2-6 alkenyl" refers to a linear, branched or cyclic alkenyl group containing at least one double bond and having 2 to 6 carbon atoms, including, for example, "C2-4 alkenyl" and the like. Examples thereof include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexadienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, 1,4-cyclohexadienyl and the like.

[0295] In the present disclosure, the term "C2-6 alkynyl" refers to a straight or branched alkynyl group containing at least one triple bond and having 2 to 6 carbon atoms, including, for example, "C2-4 alkynyl". Examples include, but are not limited to, ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3-hexynyl, 5-methyl-2-hexynyl, and the like.

[0296] In the present disclosure, the term "halogen" includes fluorine, chlorine, bromine, and iodine.

[0297] In this disclosure, the term "C3-6 cycloalkyl" refers to a saturated cyclic alkyl group containing 3 to 6 carbon atoms. Optionally, the carbon atoms in the cyclic structure may be oxo-substituted. Examples include cyclopropane (i.e., cyclopropyl), cyclobutane (i.e., cyclobutyl), cyclopentane (i.e., cyclopentyl), and cyclohexyl.

[0298] In the present disclosure, the term "C1-6 alkoxy" refers to an alkyl group as defined above attached to the parent molecular moiety through an oxygen atom, including, for example, "C1-3 alkoxy" or "C1-4 alkoxy." Specific examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.

[0299] In the present disclosure, the term "C1-6 haloalkyl" refers to an alkyl group as defined above attached to the parent molecular moiety through a halogen, including, for example, "C1-3 haloalkyl" or "C1-4 haloalkyl." Specific examples include, but are not limited to, chloromethyl, fluoroethyl, bromopropyl, and the like.

[0300] In the present disclosure, the term "4-10 membered heterocycle" refers to a ring containing 4-10 ring atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). The term "3-6 membered heterocycle" refers to a ring containing 3-6 ring atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). The term "3-7 membered heterocycle" refers to a ring containing 3-7 ring atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). The term "5-6 membered heterocycle" refers to a ring containing 5-6 ring atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). Optionally, the ring atoms (such as carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be oxoed, including but not limited to rings such as pyrrolidine, tetrahydrofuran, piperidine, piperazine, tetrahydropyran, pyrrolidone.

[0301] In this disclosure, the term "3-10 membered carbocycle" refers to a ring having 3-10 carbon atoms. Optionally, the carbon atoms in the ring structure may be oxo-substituted. Examples include 3-6 membered carbocycles, 3-7 membered carbocycles, 5-8 membered carbocycles, and the like, including but not limited to cyclopentane, cyclohexane, and the like.

[0302] In the present disclosure, the term "4-10 membered heterocyclyl" refers to a cyclic group containing 4-10 ring atoms (at least one of which is a heteroatom, such as a carbon atom, a nitrogen atom or a sulfur atom). The term "4-6 membered heterocyclyl" refers to a cyclic group containing 4-6 ring atoms (at least one of which is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulfur atom). The term "3-6 membered heterocyclyl" refers to a cyclic group containing 3-6 ring atoms (at least one of which is a heteroatom, such as a carbon atom, a nitrogen atom or a sulfur atom). Optionally, the ring atoms (such as carbon atoms, nitrogen atoms or sulfur atoms) in the cyclic structure can be oxoed. “4-8 membered heterocyclic group” includes, for example, “4-8 membered nitrogen-containing heterocyclic group”, “4-8 membered oxygen-containing heterocyclic group”, “4-7 membered heterocyclic group”, “4-7 membered oxygen-containing heterocyclic group”, “4-7 membered heterocyclic group”, “4-6 membered heterocyclic group”, “5-7 membered heterocyclic group”, “5-6 membered heterocyclic group”, “5-6 membered nitrogen-containing heterocyclic group”, including but not limited to oxocyclobutane, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, homopiperazinyl and the like.

[0303] In this disclosure, the term "aryl" refers to a monocyclic or polycyclic hydrocarbon group having aromatic properties, such as a 6-10 membered aryl group, a 5-8 membered aryl group, and the like. Specific examples include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like. The "6-10 membered aryl" refers to an aryl group containing 6-10 ring atoms. The "C6-10 aryl" refers to an aryl group containing 6-10 carbon atoms.

[0304] In the present disclosure, term " heteroaryl " refers to a cyclic group with aromaticity, wherein at least one ring atom is a heteroatom, such as a nitrogen atom, an oxygen atom or a sulphur atom. Optionally, the ring atom (such as a carbon atom, a nitrogen atom or a sulphur atom) in the ring structure can be by oxo. Specific examples include but are not limited to 5-10 yuan heteroaryl, 5-6 yuan heteroaryl, 5-10 yuan nitrogen-containing heteroaryl, 6-10 yuan oxygen-containing heteroaryl, 6-8 yuan nitrogen-containing heteroaryl, 5-8 yuan oxygen-containing heteroaryl etc., such as furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3, 4-oxadiazolyl, pyridinyl, 2-pyridonyl, 4-pyridonyl, pyrimidinyl, 1,4-dioxinyl, 2H-1,2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4-oxazinyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, 1,2,4,5-tetrazinyl, azepine, 1,3-diazacycloheptaneyl, azacyclooctatetraenyl, etc. The bonds in the structural formula represented by the wavy line "~~" in the present disclosure are intended to indicate that the structure represents a cis or trans isomer, or a mixture of cis and trans isomers in any ratio.

[0305] In this disclosure, the term "Linker Unit" refers to a component of an antibody-drug conjugate or drug-linker conjugate or linker that connects the target-binding antibody or antigen-binding fragment thereof to the rest of the antibody-drug conjugate. Linker Units can connect the T unit to Lb. Specific examples include, but are not limited to, (wherein position 1 is connected to the antibody or antigen-binding fragment thereof, and position 2 is connected to Lb or Lc):

[0306] In this disclosure, the term "linker" refers to a component of an antibody-drug conjugate or drug-linker conjugate or linker that is used to bind the linker to an amino acid residue or a short peptide consisting of 2-10 amino acid residues. When present, the linker can link La to Lc. Specific examples include, but are not limited to, (wherein position 1 is connected to the linker and position 2 is connected to Lc):

[0307] In this disclosure, the term "Spacer" refers to a component of an antibody-drug conjugate or drug-linker conjugate or linker that serves to bind a bioactive compound fragment to an amino acid residue or a short peptide consisting of 2-10 amino acid residues, or it may provide an additional structural component to further facilitate the release of the bioactive compound from the remainder of the antibody-drug conjugate. When present, the Spacer can link the Drug unit to Lc. Specific examples include, but are not limited to, (wherein position 1 is linked to Lc and position 2 is linked to D):

[0308] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.

[0309] In this disclosure, the term "antibody" is used in its broadest sense, including complete monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies) formed by at least two complete antibodies, as long as they have the desired biological activity. In this disclosure, "antibody" and "immunoglobulin" can be used interchangeably.

[0310] The term "non-engineered antibody" refers to an antibody that has not been modified to introduce additional amino acids or peptides.

[0311] The term "antibody fragment" includes a portion of an intact antibody. In a preferred embodiment, the antibody fragment is an antigen-binding fragment.

[0312] An "antigen-binding fragment" refers to a molecule, other than an intact antibody, that comprises a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; dAb (domain antibody); linear antibodies; single-chain antibodies (e.g., scFv); single-domain antibodies such as VHH; diabodies or fragments thereof; or camelid antibodies.

[0313] In this disclosure, the term "monoclonal antibody" refers to an antibody derived from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations. Monoclonal antibodies have high specificity for a single determinant (epitope) of an antigen, whereas polyclonal antibodies, in contrast, comprise different antibodies directed against different determinants (epitopes). In addition to their specificity, monoclonal antibodies have the advantage of being synthesized without contamination by other antibodies. The modifier "monoclonal" herein indicates that the antibody is characterized by being derived from a substantially homogeneous population of antibodies and should not be construed as requiring production by a specific method.

[0314] In some embodiments of the present disclosure, monoclonal antibodies also specifically include chimeric antibodies, i.e., a portion of the heavy chain and / or light chain is identical or homologous to a certain type, class, or subclass of antibody, and the remaining portion is identical or homologous to another type, class, or subclass of antibody, as long as they have the desired biological activity (see, for example, US 4,816,567; and Morrison et al., 1984, PNAS, 81: 6851-6855). Chimeric antibodies that can be used in the present disclosure include primatized antibodies, which contain variable region antigen-binding sequences from non-human primates (e.g., monkeys, orangutans, etc.) and human constant region sequences.

[0315] In the present disclosure, the "humanized" form of a non-human (e.g., mouse) antibody refers to a chimeric antibody that contains a minimal amount of non-human immunoglobulin sequence. Most humanized antibodies are those in which the hypervariable region residues of a human recipient immunoglobulin are replaced with non-human (e.g., mouse, rat, rabbit, or non-human primate) hypervariable region residues (donor antibody) having the desired specificity, affinity, and function. In some embodiments, the framework region (FR) residues of the human immunoglobulin are also replaced with non-human residues. Moreover, the humanized antibody may also include residues that are not present in the recipient antibody or the donor antibody. These modifications are to further optimize the performance of the antibody. Humanized antibodies generally include at least one, typically two, variable regions in which all or nearly all of the hypervariable loops correspond to those of a non-human immunoglobulin, while the FRs are entirely or almost entirely human immunoglobulin sequences. The humanized antibody may also include at least a portion of an immunoglobulin constant region (Fc, typically a human immunoglobulin Fc). For details, see, for example, Jones et al., 1986, Nature, 321: 522-525; Riechmann et al., 1988, Nature, 332: 323-329; and Presta, 1992, Curr Op Struct Bwl 2: 593-596.

[0316] Intact antibodies can be divided into different "classes" based on the amino acid sequence of the constant region of their heavy chains. The five main classes are IgA, IgD, IgE, IgG, and IgM, and several of these classes are further divided into different "subclasses" (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions of the different antibody classes are called α, β, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known in the art.

[0317] The monoclonal antibodies used in the present disclosure can be produced by many methods. For example, the monoclonal antibodies used in the present disclosure can be obtained by the hybridoma method using cells from many species (including mice, hamsters, rats and humans) (see, for example, Kohler et al., 1975, Nature, 256:495), or by recombinant DNA technology (see, for example, US 4,816,567), or isolated from phage antibody libraries (see, for example, Clackson et al., 1991, Nature, 352:624-628; and Marks et al., 1991, Journal of Molecular Biology, 222:581-597).

[0318] In the present disclosure, the term "multispecific antibody" includes, for example, trispecific antibodies, which are antibodies with three different antigen-binding specificities, and tetraspecific antibodies, which are antibodies with four different antigen-binding specificities.

[0319] In the present disclosure, the term "intact antibody" refers to an antibody comprising an antigen-binding variable region and a light chain constant region (CL), a heavy chain constant region (CH1, CH2, and CH3). The constant region may be a native sequence (e.g., a human native constant region sequence) or an amino acid sequence variant thereof. An intact antibody is preferably an intact antibody having one or more effector functions.

[0320] In the present disclosure, the term "probody" is a modified antibody, including an antibody or an antibody fragment, that can specifically bind to its target and can be coupled to a masking group, wherein the masking group refers to a cleavage constant for the binding ability of the antibody or antibody fragment to its target that is at least 100 times, 1000 times, or 10,000 times greater than the cleavage constant for the binding ability of the antibody or antibody fragment to its target without the coupled masking group.

[0321] Obviously, based on the above content of the present invention, according to the common technical knowledge and customary means in this field, various other forms of modification, replacement or change can be made without departing from the above basic technical concept of the present disclosure. All technologies implemented based on the above content of the present disclosure belong to the scope of the present disclosure. Beneficial effects:

[0322] The antibody-drug conjugates with multiple toxins provided by the present invention have synergistic effects on anti-tumor activity due to the different mechanisms of action of different toxins, and have significant inhibitory effects on different tumor cells tested in vivo and in vitro.

[0323] The multi-antibody drug conjugates provided by the present invention can overcome the high heterogeneity of tumors and demonstrate significant anti-tumor activity in a variety of tumors. In particular, they demonstrated strong inhibitory effects in both HER2-high (N87 and SK-BR-3) and HER2-low (H358 and MCF-7) cell lines.

[0324] The multi-warhead antibody-drug conjugates provided by the present invention utilize the extracellular cleavage ability of their linkers in the tumor microenvironment to form antibody-drug conjugates with antibodies that do not have the ability to be endocytosed, thereby compensating for the defect that traditional ADCs require endocytosis. This type of antibody-drug conjugate still has high anti-tumor activity.

[0325] The multi-warhead antibody-drug conjugate provided by the present invention utilizes the extracellular cleavage ability and enrichment ability of its linker in the tumor microenvironment to form an antibody-drug conjugate with antibodies that have no cell endocytosis ability and antibodies that have no tumor extracellular antigen binding ability. This type of antibody-drug conjugate still has high anti-tumor activity.

[0326] The multi-antibody drug conjugates provided by the present invention have anti-drug resistance effects, particularly providing a solution to the problem of drug resistance caused by single-toxin ADCs or toxins generated during treatment. In particular, they have a good inhibitory effect on cell lines resistant to camptothecin ADCs.

[0327] The multi-warhead antibody-drug conjugate preparation method of the present invention can flexibly adjust the ratio between multiple toxins, so that bioactive molecules with different mechanisms of action can produce optimal efficacy at the same ADC dose while reducing toxicity and giving the ADC an optimal safety window.

[0328] The method for preparing the multi-warhead antibody-drug conjugate of the present invention is extremely simple to operate. It does not require the synthesis of a complex multi-branched linker, multiple pretreatments of the antibody, or multiple conjugations and purifications for different sites. It has strong drugability, saves costs, and provides a good foundation for drug production. BRIEF DESCRIPTION OF THE DRAWINGS

[0329] Figure 1. In vitro proliferation inhibition rate curve of Enhertu-resistant NCI-N87 tumor cells

[0330] Figure 2. Tumor growth curve of NCI-H358 transplanted tumor model

[0331] Figure 3. Body weight change curve of mice with NCI-H358 transplanted tumor model DETAILED DESCRIPTION

[0332] The present disclosure will be further described below by way of specific embodiments, but this is not intended to limit the present disclosure to the following examples. Those skilled in the art may make various modifications or improvements based on the teachings of this disclosure without departing from the basic concept and scope of this disclosure. Reagents or instruments used without indicating the manufacturer are conventional products that can be purchased commercially.

[0333] The abbreviations in this disclosure have the following meanings:

[0334] Preparation plan

[0335] The structures of the compounds described in the following examples were determined by nuclear magnetic resonance ( 1 H NMR) or mass spectrometry (MS).

[0336] Nuclear magnetic resonance (NMR) 1 H NMR was measured using a Bruker 400 MHz nuclear magnetic resonance instrument; the measurement solvent was deuterated methanol (CD3OD), deuterated chloroform (CDCl3), or hexadeuterated dimethyl sulfoxide (DMSO-d6); and the internal standard was tetramethylsilane (TMS).

[0337] The abbreviations used in the nuclear magnetic resonance (NMR) spectra in the examples are shown below.

[0338] s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, qd: quartet doublet, ddd: double double doublet, ddt: double double triplet, dddd: double double double doublet, m: multiplet, br: broad, J: coupling constant, Hz: hertz, DMSO-d6: deuterated dimethyl sulfoxide. δ values ​​are expressed in ppm.

[0339] The mass spectrometry (MS) was performed using an Agilent (ESI) mass spectrometer, model Agilent 6120B.

[0340] 1. Preparation of Drug-Linker Conjugates

[0341] Example 1.1: Preparation of compound DL001

[0342] Step 1: Compound 1-1 (500 mg, 4.39 mmol) was dissolved in ultra-dry DCM (5 mL). Boron tribromide (1.15 g, 4.6 mmol) was added dropwise at 0°C. After the addition was complete, the mixture was warmed to room temperature and stirred for 24 hours. The reaction mixture was cooled to 0°C and methanol (5 mL) was added dropwise to quench the reaction. The reaction mixture was stirred at room temperature for another 24 hours. Saturated aqueous sodium bicarbonate solution (30 mL) was added to the reaction mixture, followed by extraction with DCM (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated to obtain 1-2 (830 mg, 92.5% yield) as a brown oil.

[0343] 1 H NMR (400MHz, CDCl3) δ3.69 (s, 3H), 3.40-3.27 (m, 2H), 2.20-2.09 (m, 2H), 1.21 (s, 6H).

[0344] Step 2: Compound 1-2 (650 mg, 3.13 mmol) was dissolved in DMF (10 mL), sodium azide (1.02 g, 15.63 mmol) was added, the temperature was raised to 80°C, stirred overnight, and then cooled to room temperature. Water (30 mL) was added to the reaction solution, and then extracted with MTBE (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried to obtain the target compound 1-3 (470 mg, yield 88.9%) as a light yellow oily liquid.

[0345] 1 H NMR (400MHz, CDCl3) δ3.69 (s, 3H), 3.31-3.23 (m, 2H), 1.89-1.81 (m, 2H), 1.22 (s, 6H).

[0346] Step 3: Compound 1-3 (365 mg, 2.13 mmol) and 5-ethynyl-2-(methylthio)pyrimidine (320 mg, 2.13 mmol) were dissolved in tert-butanol (5 mL) and water (5 mL). Sodium ascorbyl sulfate (84 mg, 0.43 mmol) and anhydrous copper sulfate (34 mg, 0.21 mmol) were added and stirred at room temperature for 1 hour. Water (25 mL) was added to the reaction solution, which was then extracted with EA (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried by spin drying. The residue was purified by silica gel column chromatography (PE:EA = 3:1) to obtain the target compound 1-4 (600 mg, 88.2% yield) as a white solid.

[0347] LCMS (ESI) [M+H] + =322.1

[0348] 1H NMR (400MHz, CDCl3) δ8.95 (s, 2H), 7.85 (s, 1H), 4.53-4.39 (m, 2H), 3.69 (s, 3H), 2.61 (s, 3H), 2.29-2.17 (m, 2H), 1.31 (s, 6H).

[0349] Step 4: Dissolve compound 1-4 (500 mg, 1.60 mmol) in THF (5 mL) and water (5 mL), add lithium hydroxide (112 mg, 4.70 mmol), and stir at room temperature for 5 hours. Add 1N hydrochloric acid to the reaction solution to adjust the pH to 3-4. A large amount of white solid will precipitate. Filter the filter cake to obtain the target compound 1-5 (450 mg, 93.5% yield) as a white solid.

[0350] LCMS (ESI) [M+H] + =308.0

[0351] 1 H NMR (400MHz, DMSO-d6) δ12.43 (s, 1H), 9.06 (s, 2H), 8.76 (s, 1H), 4.55-4.31 (m, 2H), 2.56 (s, 3H), 2.15-2.04 (m, 2H), 1.20 (s, 6H).

[0352] Step 5: Dissolve compound 1-5 (1.5 g, 4.90 mmol) in THF (10 mL) and water (10 mL), add Oxone (15.0 g, 24.5 mmol), and stir overnight at room temperature. Pour the reaction mixture into water (200 mL) and filter. The filter cake contains the target compound 1-6 (1.6 g, 93.5% yield) as a white solid.

[0353] LCMS (ESI) [M+H] + =340.1

[0354] 1 H NMR (400MHz, DMSO-d6) δ9.48 (s, 2H), 8.98 (s, 1H), 4.54-4.48 (m, 2H), 3.44 (s, 3H), 2.16-2.09 (m, 2H), 1.21 (s, 6H).

[0355] Step 6: Compound 1-6 (1.9 g, 5.32 mmol) was dissolved in DMF (40 mL), and HATU (2.13 g, 5.32 mmol) and DIEA (1.7 g, 13.3 mmol) were added. The reaction mixture was stirred at room temperature for 30 minutes. N2-(L-valine)-N6,N6-dimethylamino-L-lysine (1.45 g, 5.32 mmol) was added to the reaction mixture, and stirring was continued for 1 hour. The reaction mixture was directly purified by reverse phase chromatography (H2O:ACN = 5%-100%) to obtain the target compound 1-7 (1.5 g, 44.5% yield) as a white solid.

[0356] LCMS (ESI) [M+H] + =595.5

[0357] 1 H NMR (400MHz, DMSO-d6) δ9.51 (s, 2H), 9.05 (s, 1H), 7.89 (d, J=7.1Hz, 1H), 7.48 (d, J=8.6Hz, 1H), 4.45-4.35(m, 2H), 4.13(t, 1H), 4.07-4.09(m, 1H), 3.44(s, 3 H), 2.34 (t, J=7.3Hz, 2H), 2.23 (s, 6H), 2.19-2.06 (m, 4H), 1.73-1.57 (m, 2H), 1 .45-1.36(m, 2H), 1.31-1.27(m, 1H), 1.22(d, J=9.6Hz, 6H), 0.91-0.86(m, 6H).

[0358] Step 7: Compound 1-7 (360 mg, 0.61 mmol) and 4-aminophenethanol (75 mg, 0.61 mmol) were dissolved in DMF (5 mL). HATU (230 mg, 0.61 mmol) and DIEA (195 mg, 1.52 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was directly purified by reverse phase chromatography (H₂O:ACN = 5%-100%) to obtain the target compound 1-8 (255 mg, 60.1% yield) as a white solid.

[0359] LCMS (ESI) [M+H] + =700.4

[0360] 1H NMR (400MHz, DMSO-d6) δ9.93 (d, J=87.4Hz, 1H), 9.47 (s, 1H), 9.39 (s, 1H), 8.89 (d, J=57.3Hz, 1H), 8.54-8.16 (m, 1H), 7.68 (d, J = 7.8Hz, 0.5H), 7.56-7.48 (m, 2H), 7.47 (d, J = 8.3Hz, 0.5H), 7.19 (d, J = 8.4Hz, 1H), 7.13 (d, J =8.5Hz, 1H), 5.10-5.04(m, 1H), 4.44-4.36(m, 4H), 4.21-4.09(m, 1H), 3.45(s, 3H), 2.75-2.65(m, 2H), 2.23- 2.04(m, 4H), 1.83-1.63(m, 2H), 1.59-1.51(m, 2H), 1.42-1.35(m, 1H), 1.35-1.16(m, 12H), 0.94-0.87(m, 6H).

[0361] Step 8: Compound 1-8 (250 mg, 0.36 mmol) and 4-nitrophenyl chloroformate (288 mg, 1.43 mmol) were dissolved in DCM (10 mL), and TEA (72 mg, 0.72 mmol) was added. The mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated, and the residue was purified by reverse phase chromatography (H2O:ACN = 5%-100%) to afford 1-9 (120 mg, 38.9% yield) as a yellow solid.

[0362] LCMS (ESI) [M+H] + =865.2;

[0363] 1H NMR (400MHz, DMSO-d6) δ10.04 (d, J=73.3Hz, 1H), 9.46 (s, 1H), 9.36 (s, 1H), 8.86 (d, J=56.6Hz, 1H), 8.31 (d, J=9.1Hz, 2H), 8.08 (d, J=9.2Hz, 1H), 7.64 (d, J=8.0Hz, 1H), 7.59-7.55 (m, 3H), 7.42 (d, J=8.3Hz, 1H), 7.37 (d, J=8.5Hz, 1H), 7.27 (d, J=8. 5Hz, 1H), 6.83 (d, J = 9.1Hz, 1H), 5.19 (d, J = 14.8Hz, 2H), 4.45-4.38 (m, 2H), 4.37-4.28 (m, 1H), 4.21-4.14 (m, 1H), 3.44 (s, 3H), 2.18-2.12(m, 3H), 2.10-2.06(m, 8H), 1.81-1.63(m, 2H), 1.44-1.32(m, 4H), 1.23(d, J=7.4Hz, 7H), 0.94-0.88(m, 6H).

[0364] Step 9: Dissolve compound 1-9 (36 mg, 0.041 mmol) and eribulin (20 mg, 0.027 mmol) in DMF (2 mL). Add DIEA (7 mg, 0.054 mmol). After complete addition, stir the reaction mixture at room temperature for 1 hour. The crude product was purified by preparative chromatography (0.01% FA in water, ACN) to afford the target compound DL001 (21.8 mg, 52.6% yield) as a white solid.

[0365] LCMS (ESI) [M+H] + =1455.6;

[0366] 11H NMR (400 MHz, DMSO-d6) δ 10.01 (d, J = 69.6 Hz, 1H), 9.46 (s, 1H), 9.39 (s, 1H), 8.88 (d, J = 47.0 Hz, 1H), 8.50 (d, J = 7.3 Hz, 0.5H), 8.37 (s, 2H), 8.16 (d, J = 6.7 Hz, 0.5H), 7.67 - 7.46 (m, 3H), 7.23 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.07 (t, J = 5.4 Hz, 1H), 5.05 (s, 1H), 4.99 (s, 1H), 4.90 (d, J = 3.6 Hz, 1H), 4.87 (s, 1H), 4.83 (s, 1H), 4.75 (s, 1H), 4.63 (s, 1H), 4.55 (t, J = 4.0 Hz, 1H), 4.43 - 4.33 (m, 3H), 4.26 (d, J = 10.3 Hz, 1H), 4.21 - 4.14 (m, 2H), 4.11 (d, J = 10.6 Hz, 4H), 4.01 (d, J = 9.8 Hz, 1H), 3.84 - 3.73 (m, 4H), 3.72 - 3.65 (m, 3H), 3.44 (s, 3H), 3.27 - 3.22 (m, 5H), 2.96 (t, J = 5.6 Hz, 2H), 2.84 (d, J = 9.5 Hz, 1H), 2.80 - 2.64 (m, 3H), 2.60 - 2.55 (m, 1H), 2.36 - 2.29 (m, 2H), 再看2.27 - 2.23 (m, 2H), 2.21 - 2.11 (m, 6H), 2.08 (d, J = 4.8 Hz, 6H), 2.06 - 2.03 (m, 1H), 2.03 - 1.95 (m, 2H), 1.94 - 1.88 (m, 4H), 1.74 - 1.60 (m, 7H), 1.如果56 - 1.看45 (m, 3H), 1.38 - 1.28 (m, 6H), 1.24 - 1.20 (m, 6H), 1.03 (d, J = 6.3 Hz, 3H), 0.97 (d, J = 12.0 Hz, 1H), 0.92 - 0.86 (m, 6H).

[0367] Example 1.2: Preparation of Compound DL002

[0368] 说明:原文中存在部分不太清晰的表述(如“再看2.27 - 2.23 (m, 2H), 2.21 - 2.11 (m, 6H), 2.08 (d, J = 4.8 Hz, 6H), 2.如果56等等”),按照要求尽量准确翻译,但这部分内容可能会影响对整体含义的理解。Step 1: Dissolve compound 2-1 (5.0 g, 9.07 mmol) in DCM / anhydrous methanol (5 / 1) (50 mL), add p-aminobenzyl alcohol (1.1 g, 9.07 mmol) and EEDQ (4.5 g, 18.2 mmol), and stir at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and purified by silica gel chromatography (DCM:anhydrous methanol = 20:1) to obtain compound 2-2 (3.1 g, yield: 52.0%) as a yellow solid.

[0369] LCMS (ESI) [M+H] + =657.5;

[0370] 1 H NMR (400MHz, DMSO-d6) δ10.05 (s, 1H), 8.15 (d, J=7.5Hz, 1H), 7.90 (d, J=7.5Hz, 2H), 7.74 (d, J= 7.5Hz, 2H), 7.55 (d, J=8.4Hz, 2H), 7.50-7.39 (m, 3H), 7.32 (t, J=7.4Hz, 2H), 7.24 (d, J=8.3Hz, 2H), 5.11 (t, J=5.6Hz, 1H), 4.43 (d, J=5.4Hz, 3H), 4.34-4.16 (m, 3H), 3.92 (t, J=8.0Hz, 1H), 3. 01-2.84(m, 6H), 2.03-1.96(m, 1H), 1.80-1.53(m, 8H), 1.41-1.27(m, 2H), 0.91-0.83(m, 12H).

[0371] Step 2: Dissolve compound 2-2 (2.5 g, 3.81 mmol) in DMF (35 mL), add DEA (557 mg, 7.62 mmol), and react at room temperature for 1 h. The reaction solution is concentrated under reduced pressure to remove DEA to obtain compound 2-3 (1.65 g, crude product).

[0372] LCMS (ESI) [M+H] + =435.4;

[0373] Step 3: Dissolve compound 2-3 (1.65 g, 3.81 mmol) in DMF (35 mL), add 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (1.02 g, 3.81 mmol), HATU (1.45 g, 3.81 mmol), and DIEA (1.23 g, 9.53 mmol), and react at room temperature for 2 h. The reaction solution was purified by reverse phase chromatography (0.05% TFA in water, ACN) to obtain compound 2-4 (1.1 g, 42.3% yield) as a white solid.

[0374] LCMS (ESI) [M+H] + =685.4;

[0375] 1 H NMR (400MHz, DMSO-d6) δ9.88 (s, 1H), 9.11 (s, 2H), 8.05 (d, J = 7.6Hz, 1H), 7.94 (d, J = 8.5Hz, 1H), 7. 54 (d, J=8.4Hz, 2H), 7.22 (d, J=8.3Hz, 2H), 5.09 (t, J=4.8Hz, 1H), 4.42 (d, J=3.4Hz, 2H), 4.39-4.33 (m, 1H), 4.24-4.18 (m, 1H), 3.4l (s, 3H), 2.56 (t, J=7.1Hz, 2H), 2.45-2.29 (m, 7H), 2.03-1.96 (m, 2H ), 1.87-1.78(m, 2H), 1.76-1.68(m, 1H), 1.67-1.58(m, 1H), 1.45-1.26(m, 8H), 0.90-0.78(m, 12H).

[0376] Step 4: Under nitrogen, compound 2-4 (510 mg, 0.746 mmol) was dissolved in ultra-dry DCM (10 mL). Di(p-nitrobenzene) carbonate (453 mg, 1.491 mmol) and DIEA (192 mg, 1.491 mmol) were added and allowed to react for 2 h. The reaction solution was purified by reverse-phase chromatography (0.05% TFA in water, ACN) to afford compound 2-5 (300 mg, 44.7% yield) as a pale yellow solid.

[0377] LCMS (ESI) [M+H] + =850.4;

[0378] 1H NMR (400MHz, DMSO-d6) δ10.10 (s, 1H), 9.11 (s, 2H), 8.34-8.28 (m, 2H), 8.19 (d, J=7.1Hz, 1H), 7.94 (d , J=8.2Hz, 1H), 7.65 (d, J=8.5Hz, 2H), 7.59-7.53 (m, 2H), 7.42 (d, J=8.6Hz, 2H), 5.24 (s, 2H), 4.43-4 .36 (m, 1H), 4.23-4.18 (m, 1H), 3.41 (s, 3H), 3.05-2.95 (m, 6H), 2.57 (d, J=7.2Hz, 2H), 2.44-2.36 (m, 2H), 2.36-2.27(m, 2H), 2.03-1.94(m, 1H), 1.88-1.75(m, 3H), 1.67-1.54(m, 7H), 0.92-0.84(m, 12H).

[0379] Step 5: Eribulin (50 mg, 0.07 mmol) was dissolved in DMF (1.5 mL). Compound 2-5 (58 mg, 0.07 mmol) and DIEA (22 mg, 0.18 mmol) were added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was directly purified by reverse-phase chromatography (0.05% TFA in water, ACN) to obtain the target compound DL002 (52 mg, 53% yield).

[0380] LCMS (ESI) [M+H] + =1441.2;

[0381] 1H NMR (400MHz, DMSO-d6) δ10.02 (s, 1H), 9.11 (s, 2H), 8.98 (s, 1H), 8.17 (d, J=7.8Hz, 1H), 7.94 (d, J=8.6Hz, 1H), 7.58 (d, J=8.4Hz, 2H), 7.28 (d, J=8.5Hz, 2H), 7.06 (t, J=6.5Hz, 1H), 5.05 (s, 1H), 5 .00 (s, 1H), 4.93 (d, J=3.3Hz, 2H), 4.83 (s, 1H), 4.75 (s, 1H), 4.65-4.62 (m, 1H), 4.57-4.53 (m, 1H ), 4.43-4.35(m, 2H), 4.30-4.24(m, 2H), 4.21-4.17(m, 2H), 4.11-4.09(m, 3H), 4.04-4.00(m, 2H) , 3.84-3.73(m, 4H), 3.72-3.64(m, 2H), 3.57-3.46(m, 4H), 3.41(s, 3H), 3.28-3.22(m, 4H), 3.05- 2.94 (m, 9H), 2.84 (d, J=9.9Hz, 1H), 2.79-2.63 (m, 3H), 2.60-2.53 (m, 4H), 2.44-2.36 (m, 2H), 2.3 5-2.29(m, 3H), 2.28-2.23(m, 2H), 2.21-2.11(m, 2H), 2.02-1.97(m, 2H), 1.94-1.91(m, 3H), 1.85 -1.79 (m, 2H), 1.69-1.57 (m, 11H), 1.36-1.27 (m, 5H), 1.03 (d, J=6.5Hz, 3H), 0.91-0.83 (m, 12H).

[0382] Example 1.3: Preparation of compound DL003

[0383] DL003 was prepared according to the method of WO2022170971.

[0384] Example 1.4: Preparation of compound DL004

[0385] Step 1: Dissolve MMAE (108 mg, 0.15 mmol) in DMF (2 mL). Add compound 1-9 (130 mg, 0.15 mmol), 1-hydroxybenzotriazole (20.3 mg, 0.15 mmol), and DIEA (58.2 mg, 0.45 mmol) sequentially. React at room temperature for 4 h. The reaction solution is directly purified by preparative HPLC (0.1% FA in water, ACN) to obtain the target compound DL004 (55 mg, 25.4% yield).

[0386] LCMS (ESI) [M / 2+H] + =722.52

[0387] 1 H NMR (400MHz, DMSO-d6) δ10.06 (s, 1H), 9.46 (s, 2H), 8.93 (s, 1H), 8.22 (s, 1H), 8.10 (d, J=7.3Hz, 1H), 8. 02 (d, J=8.5Hz, 0.5H), 7.88 (d, J=8.7Hz, 0.5H), 7.61 (d, J=8.5Hz, 0.5H), 7.56-7.50 (m, 2H), 7.42 (d, J=8 .4Hz, 1H), 7.35-7.08(m, 7.5H), 5.09-4.94(m, 2H), 4.76-4.38(m, 6H), 4.29-4.16(m, 2H), 4.08-3.91(m, 3H), 3.81-3.75(m, 1H), 3.24-2.82(m, 15H), 2.45-1.27(m, 31H), 1.25-1.19(m, 6H), 1.05-0.75(m, 30H).

[0388] Example 1.5: Preparation of compound DL005

[0389] Step 1: Dissolve compound 5-1 (10 g, 20.2 mmol) in DCM / anhydrous methanol (5 / 1) (36 mL). Add p-aminobenzyl alcohol (2.5 g, 20.2 mmol) and EEDQ (10 g, 40.4 mmol). Stir at room temperature for 2 h. The reaction mixture is concentrated and purified by column chromatography (DCM:methanol = 15:1) to obtain the target compound 5-2 (7 g, 57.9% yield) as a white solid.

[0390] LCMS (ESI) [M+H] + =601.4;

[0391] 1H NMR (400MHz, DMSO-d6) δ10.09 (s, 1H), 8.18 (d, J = 7.7Hz, 1H), 7.90 (d, J = 7.5Hz, 2H), 7.79-7.72 (m, 2H) , 7.56 (d, J = 8.4Hz, 2H), 7.48-7.39 (m, 3H), 7.33 (t, J = 7.4Hz, 2H), 7.23 (d, J = 8.4Hz, 2H), 4.47-4.40 (m , 3H), 4.34-4.28(m, 1H), 4.25-4.20(m, 2H), 3.96-3.90(m, 1H), 3.02-2.92(m, 2H), 2.69(s, 3H), 2.68( s, 3H), 2.07-1.96 (m, 1H), 1.83-1.73 (m, 1H), 1.71-1.60 (m, 3H), 1.42-1.29 (m, 2H), 0.90-0.85 (m, 6H).

[0392] Step 2: Dissolve compound 5-2 (3.5 g, 5.8 mmol) in DMF (15 mL), add DEA (852 mg, 11.7 mmol), and stir at room temperature for 1 h. The reaction solution is concentrated under reduced pressure to obtain compound 5-3 (2.2 g, crude), which is used directly in the next reaction.

[0393] LCMS (ESI) [M+H] + =379.3;

[0394] Step 3: 6-(2-(Methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (1.34 g, 5.02 mmol) was dissolved in DMF (10 mL). HATU (1.9 g, 5.02 mmol) and DIEA (1.61 g, 12.56 mmol) were added sequentially. The mixture was stirred at 25°C for 0.5 h. Compound 5-3 (1.9 g, 5.02 mmol) was then added and stirred at 25°C for 1 h. The reaction mixture was purified by reverse phase column chromatography (0.1% TFA in water, ACN) to obtain the target compound 5-4 (2 g, yield: 55.6%).

[0395] LCMS (ESI) [M+H] + =629.6;

[0396] 1H NMR (400MHz, DMSO-d6) δ9.93 (s, 1H), 9.12 (s, 2H), 8.16 (d, J = 7.6Hz, 1H), 7.95 (d, J = 8.4Hz, 1H), 7.54 ( d, J=8.4Hz, 2H), 7.23 (d, J=8.4Hz, 2H), 4.42 (s, 2H), 4.40-4.35 (m, 1H), 4.23-4.18 (m, 1H), 3.41 (s, 3H) ), 3.41-3.40(m, 1H), 3.06-2.98(m, 2H), 2.75(s, 3H), 2.74(s, 3H), 2.56(t, J=7.0Hz, 2H), 2.41-2.33( m, 2H), 2.01-1.95 (m, 1H), 1.87-1.80 (m, 2H), 1.68-1.59 (m, 3H), 1.38-1.27 (m, 2H), 0.89-0.82 (m, 6H).

[0397] Step 4: Compound 5-4 (1.8 g, 2.87 mmol) was dissolved in DMF (10 mL), and di(p-nitrobenzene) carbonate (1.74 g, 5.74 mmol) and DIEA (740 mg, 5.74 mmol) were added. The mixture was stirred at 25°C for 2 h. LCMS analysis indicated that the reaction was nearly complete. The reaction solution was slurried with MTBE (80 mL) and then anhydrous ether (100 mL) to obtain the target compound 5-5 (1.8 g, yield: 79.1%) as a light yellow solid.

[0398] LCMS (ESI) [M+H] + =794.6;

[0399] 1H NMR (400MHz, DMSO-d6) δ10.08 (s, 1H), 9.11 (s, 2H), 8.31 (d, J=9.1Hz, 2H), 8.17 (d, J=7.5Hz, 1H), 7.93 (d, J=8. 5Hz, 1H), 7.64 (d, J=8.5Hz, 2H), 7.56 (d, J=9.1Hz, 2H), 7.41 (d, J=8.5Hz, 2H), 5.24 (s, 2H), 4.44-4.36 (m, 1H), 4 .25-4.17(m, 1H), 3.41(s, 3H), 2.90-2.79(m, 2H), 2.68-2.57(m, 6H), 2.58-2.54(m, 2H), 2.42-2.31(m, 2H), 2.0 5-1.92(m, 1H), 1.88-1.78(m, 2H), 1.77-1.62(m, 2H), 1.61-1.53(m, 2H), 1.41-1.26(m, 2H), 0.89-0.82(m, 6H).

[0400] Step 5: Dissolve MMAE (108 mg, 0.15 mmol) in DMF (2 mL), compound 5-5 (119 mg, 0.15 mmol), 1-hydroxybenzotriazole (20.3 mg, 0.15 mmol), and DIEA (58.2 mg, 0.45 mmol) in DMF (2 mL). The mixture was reacted at 22°C for 4 h. The reaction solution was directly purified by preparative HPLC (0.1% FA in water, ACN) to obtain the target compound DL005 (75 mg, yield: 36.4%).

[0401] LCMS (ESI) [M / 2+H] + =686.98

[0402] 1H NMR (400MHz, DMSO-d6) δ10.07-9.86 (m, 1H), 9.11 (s, 2H), 8.22 (s, 1H), 8.14-7.98 (m, 2H), 7.96-7.85 ( m, 1.5H), 7.66-7.50 (m, 2.5H), 7.36-7.23 (m, 6H), 7.21-7.09 (m, 1H), 5.60-5.19 (m, 1H), 5.13-4.90 (m , 2H), 4.79-4.55(m, 1H), 4.54-4.14(m, 6H), 4.08-3.87(m, 3H), 3.83-3.74(m, 1H), 3.20-2.82(m, 14H) , 2.55 (t, J=7.1Hz, 2H), 2.44-2.21 (m, 7H), 2.15-1.28 (m, 26H), 1.06-0.97 (m, 6H), 0.88-0.74 (m, 24H).

[0403] Example 1.6: Preparation of compound DL006

[0404] Step 1: Compound 6-2 (35.35 g, 143.53 mmol) was weighed and added to a solution of NaHCO3 (24.12 g, 287.06 mmol) in water (250 mL). A solution of 6-1 (50.0 g, 143.53 mmol) in THF (250 mL) was added dropwise under an ice-water bath. After the addition was complete, the reaction system was stirred at room temperature for 4 h. The reaction solution was concentrated to remove the organic solvent and then adjusted to pH 5 with hydrochloric acid (4 mol / L). After stirring for 1 h, the mixture was filtered. The filter cake was slurried with DCM (700 mL) for 30 mins, filtered, and dried to obtain the desired product 6-3, 65.0 g, in a yield of 94.5%.

[0405] 1 H NMR (400MHz, DMSO-d6) δ8.07 (d, J=8.0Hz, 1H), 7.36-7.30 (m, 5H), 7.23 (d, J=8.0Hz, 1H), 6.74 (t, J=8Hz, 1H), 5.04 (s, 2H), 4.18-4.12 (m, 1 H), 3.94-3.90(m, 1H), 2.91-2.87(m, 2H), 1.97-1.85(m, 1H), 1.74-1.64(m, 1H), 1.62-1.52(m, 1H), 1.42-1.23(m, 13H), 0.90-0.83(m, 6H).

[0406] Step 2: Weigh compound 6-3 (50.0 g, 104.26 mmol) and add it to THF (20 mL), then add concentrated hydrochloric acid (17.2 mL, 206.40 mmol), heat at 60°C for 1 h, cool the reaction solution to room temperature and use it directly in the next step.

[0407] 1 H NMR (400MHz, DMSO-d6) δ12.59 (s, 1H), 8.19 (d, J=8.0Hz, 1H), 7.96 (s, 3H), 7.40-7.34 (m, 5H), 8.27 (d, J=8.0Hz, 1H), 5.06 (s, 2H), 4. 22-4.17(m, 1H), 3.96-3.92(m, 1H), 2.80-2.77(m, 2H), 2.04-2.00(m, 1H), 1.63-1.57(m, 4H), 1.41-1.39(m, 2H), 0.93-0.87(m, 6H).

[0408] Step 3: Add THF (300 mL) to the solution obtained in step 2, add sodium cyanoborohydride (19.7 g, 312.78 mmol) and n-propanal (24.3 g, 417.04 mmol) under ice-water bath. Warm to room temperature and stir the reaction for 1 hour. Add hydrochloric acid to adjust the pH to 4-5 and stir for 30 minutes. The reaction system is concentrated to remove THF, water (200 mL) and DCM (200 mL) are added, and the organic phase is collected. 60.0 g of anhydrous sodium sulfate is added to the aqueous phase and extracted again with DCM (100 mL). The organic phases are combined, dried over anhydrous sodium sulfate, insoluble matter is filtered off, and concentrated to obtain the target compound 6-5, 38.0 g, with a two-step yield of 78.6%.

[0409] 1 H NMR (400MHz, DMSO-d6) δ7.93 (d, J=8.0Hz, 1H), 7.35-7.26 (m, 6H), 5.03 (s, 2H), 4.15-4.10 (m, 1H), 3.91-3.87(m, 1H), 2.76-2.58(m, 6H), 2.00-1.96(m, 1H), 1.82-1.19(m, 10H), 0.89-0.84(m, 12H).

[0410] Step 4: Compound 6-6 (5 g, 17.84 mmol) was added to trifluoroethanol (30 mL) under argon protection and stirred at 40°C to dissolve. HCl in DMF (2.1 mL, 0.4 mol / L) was then added and stirred at 40°C for 2.5 h. The reaction mixture was cooled to room temperature and added to 120 mL of aqueous sodium bicarbonate (1%, w / v), stirred, filtered, and the filter cake was dried to obtain the target compound 6-7, 5.3 g, in a yield of 92.8%.

[0411] 1 H NMR (400MHz, DMSO-d6) δ8.88 (t, J=6.5Hz, 1H), 7.54 (t, J=6.0Hz, 1H), 7.40-7.32 (m, 5 H), 5.07 (s, 2H), 4.70 (d, J=6.8Hz, 2H), 4.03 (q, J=9.4Hz, 2H), 3.68 (d, J=6.1Hz, 2H).

[0412] Step 5: Dissolve compound 6-7 (1.00 g, 3.29 mmol) in THF (5 ml), add 5% Pd / C (50 mg), replace the atmosphere with hydrogen, and react at room temperature for 3 h. Add DMF (5 mL), filter, and concentrate to remove THF to obtain a DMF solution of the target compound 6-8 in quantitative yield, which was used directly in the next reaction.

[0413] The HOBt salt of compound 6-8 has a H NMR spectrum of: 1 H NMR (400MHz, DMSO-d6) δ9.18 (br, 1H), 7.79-7.71 (m, 1H), 7.49-7.41 (m, 1H), 7.25-7.18 (m, 2H), 4.74 (d, J=4.9Hz, 2H), 4.06 (q, J=9.4Hz, 2H), 3.47 (s, 2H).

[0414] Step 6: Add compound 6-5 (1.52 g, 3.29 mmol) to the DMF solution of compound 6-8 obtained in step 5, control the temperature at -10°C, add DMTMM (1.16 g, 3.98 mmol) and react for 1.5 h. Add EA (50 mL) to the reaction system, wash with saturated NaHCO3 aqueous solution (15 mL*3) and saturated brine (15 mL) in sequence, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate the filtrate. The resulting residue is dissolved in EA (3 mL), added to n-heptane (30 mL), stirred to precipitate a solid, and filtered. The filter cake is the target compound 6-9, 1.55 g, with a yield of 74.9%.

[0415] LCMS (ESI) [M+H] + =632.3.

[0416] 1 H NMR (400MHz, DMSO-d6) δ8.85-8.73 (m, 1H), 8.37-8.26 (m, 1H), 8.03 (d, J=7.0Hz, 1H ), 7.40-7.32(m, 6H), 5.10-5.01(m, 2H), 4.73-4.66(m, 2H), 4.29-4.20(m, 1H), 4.0 2(q, J=9.4Hz, 2H), 3.93(dd, J=13.8, 6.6Hz, 1H), 3.85-3.67(m, 2H), 2.38-2.32(m, 6H), 2.02-1.96(m, 1H), 1.75-1.51(m, 2H), 1.46-1.23(m, 8H), 0.90-0.82(m, 12H).

[0417] Step 7: Compound 6-9 (4 g, 6.3 mmol) was dissolved in 100 mL of methanol and subjected to a fully automated micro-reactor hydrogenation process using alumina-supported palladium hydroxide as a catalyst. The reaction was performed under the following conditions: temperature 50°C, pressure 2.5 MPa, feed liquid flow rate 0.3 mL / min, and hydrogen flow rate 30 mL / min. The effluent solution was concentrated under reduced pressure to afford the target compound 6-10, 3.0 g, in a 95.1% yield.

[0418] LCMS (ESI) [M+H] + =498.3.

[0419] 1 H NMR (400MHz, DMSO-d6) δ8.89-8.77(m, 1H), 8.42-8.30(m, 1H), 8.14(s, 1H), 4.70( p, J=10.3Hz, 2H), 4.28 (s, 1H), 4.02 (q, J=9.4Hz, 2H), 3.80 (dd, J=15.7, 4.9Hz, 1H) , 3.75-3.67 (m, 1H), 3.20 (s, 1H), 3.11 (d, J = 4.8Hz, 1H), 2.35 (dd, J = 14.4, 7.3Hz, 6H), 2.04-1.90(m, 1H), 1.76-1.51(m, 2H), 1.45-1.20(m, 8H), 0.95-0.77(m, 12H).

[0420] Step 8: Dissolve compound 6-10 (50.0 g, 100 mmol) in 350 mL of ACN, cool to 10°C, add DIPEA (3.25 g, 25 mmol), and dropwise add a solution of compound 6-11 (prepared from 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid and thionyl chloride, used fresh) (34.4 g, 120 mmol) in ACN (150 mL). The reaction was allowed to proceed for 1 h. 2-Methyltetrahydrofuran (2.1 L) was added to the reaction solution. The precipitated solid was filtered and the filter cake dried to afford the hydrochloride salt of target compound 6-12 (71.8 g, 91.6% yield).

[0421] LCMS (ESI) [M+H] + =748.4

[0422] 1 H NMR (400MHz, DMSO-d6) δ9.15 (s, 2H), 8.78 (t, J = 6.8Hz, 1H), 8.24 (t, J = 5.8Hz, 1H), 8.05 (d, J = 7.3Hz , 1H), 7.95 (d, J=8.6Hz, 1H), 4.75-4.66 (m, 2H), 4.24-4.19 (m, 2H), 4.03 (q, J=9.4Hz, 2H), 3.78-3.7 6(m, 2H), 3.44(s, 3H), 2.58(t, J=7.1Hz, 2H), 2.46-2.29(m, 8H), 2.03-1.95(m, 1H), 1.89-1.81(m, 2 H), 1.73-1.66 (m, 1H), 1.62-1.56 (m, 1H), 1.41-1.36 (m, 6H), 1.31-1.25 (m, 2H), 0.89-0.83 (m, 12H).

[0423] Step 9: Compound 6-13 (100.00 mg, 0.13 mmol) was dissolved in DMF (1 mL). N-methylhydroxyethylamine (9.76 mg, 0.13 mmol) was added to the solution, and the mixture was cooled to -5°C with stirring. DMTMM (53.96 mg, 0.20 mmol) was then added. The reaction mixture was stirred for 2 h. The reaction solution was directly purified by preparative HPLC (0.05% FA in water, ACN) to obtain the target compound 6-14 (57 mg, yield: 54.6%).

[0424] LCMS (ESI) [M / 2+H] + =402.56;

[0425] 1H NMR (400MHz, DMSO-d6) δ8.55-8.44(m, 0.5H), 8.32-8.17(m, 0.5H), 8.13-7.98(m, 1H), 7.32-7.08(m, 5H), 5.25-4.80(m, 2 H), 4.78-4.40(m, 3H), 3.99-3.49(m, 6H), 3.25-3.14(m, 8H), 3.09-2.62(m, 10H), 2.38-1.29(m, 17H), 1.01-0.69(m, 21H).

[0426] Step 10: Compound 6-14 (47.00 mg, 0.057 mmol) was dissolved in DMF (0.5 mL), and the hydrochloride salt of 6-12 (138.25 mg, 0.17 mmol) and HCl-DMF (4 M, 0.5 mL) were added. The reaction mixture was stirred at 25°C for 5 h; the reaction was monitored by LCMS; the reaction mixture was directly purified by preparative HPLC (0.1% TFA in water, ACN) to obtain the target compound DL006 (8 mg, yield: 8.4%).

[0427] LCMS (ESI) [M / 3+H] + =484.85;

[0428] 1 H NMR (400MHz, DMSO-d6) δ9.65-9.49(m, 1H), 9.20-9.05(m, 3H), 8.99-8.89(m, 1H), 8.72-8.61(m, 1H), 8.58-8.46(m , 0.5H), 8.37-8.25 (m, 0.5H), 8.24-8.18 (m, 1H), 8.14-8.07 (m, 1H), 7.99-7.90 (m, 1H), 7.29-7.16 (m, 5H), 5.09-4 .54(m, 6H), 4.29-4.16(m, 2H), 4.03-3.97(m, 1H), 3.79-3.72(m, 3H), 3.33-3.18(m, 10H), 3.10-2.98(m, 12H), 2.9 1-2.68(m, 11H), 2.46-2.20(m, 7H), 2.16-1.95(m, 3H), 1.89-1.58(m, 14H), 1.55-1.26(m, 6H), 1.05-0.78(m, 35H).

[0429] Example 1.7: Preparation of compound DL007

[0430] Step 1: Dissolve compound 6-13 (30 mg, 0.040 mmol) in DMF (0.5 mL), add N-methylhydroxypropylamine (10.7 mg, 0.12 mmol), cool the temperature to -5°C, add DMTMM monohydrate (15.3 mg, 0.052 mmol), and react for 1 h. The reaction solution was directly purified by preparative HPLC (0.1% TFA in water / ACN) to obtain the target compound 7-1 (17 mg, yield: 45.6%).

[0431] LCMS (ESI) [M / 2+H] + =409.57

[0432] 1 H NMR (400MHz, DMSO-d6) δ9.61 (s, 1H), 9.05-8.84 (m, 1H), 8.56 (d, J=8.7Hz, 0.5 H), 8.36-8.22(m, 0.5H), 7.33-7.16(m, 5H), 5.16-4.83(m, 1H), 4.79-4.56(m, 2 H), 4.05-3.92(m, 1H), 3.84-3.69(m, 2H), 3.37-3.21(m, 8H), 3.11-2.99(m, 5H) , 2.87-2.74(m, 9H), 2.50-1.97(m, 6H), 1.93-1.20(m, 9H), 1.09-0.73(m, 25H).

[0433] Step 2: Dissolve compound 7-1 (30 mg, 0.035 mmol) in DMF (0.5 mL), add the hydrochloride salt of 6-12 (87 mg, 0.11 mmol) and HCl-DMF (4 M, 0.5 mL), and react at room temperature for 5 h. The reaction solution was directly purified by preparative HPLC (0.1% TFA in water / ACN) to obtain the trifluoroacetic acid salt of the target compound DL007 (13 mg, yield: 23.8%).

[0434] LCMS (ESI) [M / 3+H] + =489.29

[0435] 1H NMR (400MHz, DMSO-d6) δ9.57 (s, 1H), 9.19-9.02 (m, 3H), 8.99-8.83 (m, 1H), 8.67-8.53 (m, 1H), 8.52-8.45 ( m, 0.5H), 8.33-8.21 (m, 0.5H), 8.17 (t, 1H), 8.08 (t, J=6.9Hz, 1H), 7.96-7.84 (m, 1H), 7.25-7.13 (m, 5H), 5. 03-4.40(m, 6H), 4.28-4.13(m, 2H), 4.00-3.93(m, 1H), 3.76-3.70(m, 3H), 3.33-3.14(m, 12H), 3.07-2.97(m , 9H), 2.83-2.73 (m, 9H), 2.55 (t, J=7.1Hz, 2H), 2.46-1.90 (m, 9H), 1.88-1.18 (m, 22H), 1.03-0.73 (m, 37H).

[0436] Example 1.8: Preparation of compound DL008

[0437] Step 1: Dissolve compound 9-1 (5 g, 8.8 mmol) in a mixture of DCM (30 mL) and methanol (6 mL). Add p-aminobenzyl alcohol (1.1 g, 8.8 mmol) and EEDQ (4.3 g, 17.6 mmol). Stir at room temperature for 2 h. The reaction mixture is concentrated and purified by column chromatography (DCM:methanol = 20:1) to obtain the target compound 8-1 (2.5 g, 42.4% yield).

[0438] LCMS (ESI) [M+H] + =673.5;

[0439] 1H NMR (400MHz, DMSO-d6) δ9.94 (s, 1H), 8.04 (d, J = 7.6Hz, 1H), 7.89 (d, J = 7.5Hz, 2H), 7.74 (t, J = 8.0Hz, 2H), 7.53 (d, J=8.4Hz, 2H), 7.47-7.38 (m, 3H), 7.32 (t, J=7.4Hz, 2H), 7.23 (d, J=8.4Hz, 2H), 6.72 (t, J=5.2Hz, 1H), 5.09 (t, J=5.7Hz, 1H), 4.48-4.34 (m, 3H), 4.32-4.17 (m, 3H), 3.96-3.87 (m, 1H), 2.95-2.77 (m, 2H), 2 .06-1.92(m, 1H), 1.65(d, J=30.4Hz, 2H), 1.41-1.35(m, 2H), 1.33(s, 9H), 1.24(s, 2H), 0.92-0.82(m, 6H).

[0440] Step 2: Dissolve compound 8-1 (3 g, 4.46 mmol) in DMF (15 mL), add DEA (391 mg, 5.36 mmol), and stir at 25°C for 1 h. The reaction solution was concentrated by rotary evaporation to obtain the target compound 8-2 (2.0 g, yield: 95.8%) as a colorless oil.

[0441] LCMS (ESI) [M+H] + =451.1;

[0442] Step 3: Dissolve 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (1.2 g, 4.46 mmol) in DMF (15 mL). Add HATU (1.7 g, 4.46 mmol) and DIPEA (1.4 g, 11.15 mmol) sequentially. Stir at 25°C for 0.5 h. Add 8-2 (2 g, 4.46 mmol), and stir at 25°C for 1 h. The reaction mixture is purified by reverse phase column chromatography (ACN / H2O containing 0.1% TFA = 5%-60%) to obtain the target compound 8-3 (1 g, yield: 37.0%).

[0443] LCMS (ESI) [M+H] + =701.5;

[0444] 1H NMR (400MHz, DMSO-d6) δ9.87 (s, 1H), 9.11 (s, 2H), 8.05 (d, J = 7.8Hz, 1H), 7.93 (d, J = 8.5Hz, 1H), 7.53 (d, J = 8.5Hz , 2H), 7.22 (d, J=8.3Hz, 2H), 6.75 (t, J=4.4Hz, 1H), 5.08 (t, J=5.6Hz, 1H), 4.42 (d, J=5.6Hz, 2H), 4.38-4.30 (m, 1H ), 4.21 (t, J = 7.5Hz, 1H), 3.41 (s, 3H), 2.92-2.84 (m, 2H), 2.55 (t, J = 7.3Hz, 3H), 2.43-2.38 (m, 1H), 2.37-2.32 (m , 1H), 2.03-1.96(m, 2H), 1.881.79(m, 2H), 1.73-1.54(m, 2H), 1.52-1.38(m, 2H), 1.35(s, 9H), 0.88-0.83(m, 6H).

[0445] Step 4: Dissolve compound 8-3 (1.0 g, 1.43 mmol) in DMF (10 mL), add di(p-nitrobenzene) carbonate (869 mg, 2.86 mmol) and DIPEA (369 mg, 2.86 mmol), and stir at 25°C for 2 h. Add MTBE (80 mL) to the reaction mixture and stir for 1 h. Filter with suction. The filter cake is stirred with anhydrous ether (80 mL) for 1 h, filtered, and dried to obtain the target compound 8-4 (1.1 g, yield: 89.4%).

[0446] LCMS(ESI)[M+H-Boc] + =766.4;

[0447] 1H NMR (400MHz, DMSO-d6) δ10.06 (s, 1H), 9.12 (s, 2H), 8.35-8.28 (m, 2H), 8.00-7.89 (m, 2H), 7.64 (d, J=8.5Hz, 2H), 7.59-7.54 (m, 2H), 7.41 (d, J=8.6Hz, 2H), 6.78 (t, J=5.3Hz, 1H), 5.23 (s, 2H), 4.39-4.30 (m, 1H), 4.27- 4.18 (m, 1H), 3.41 (s, 3H), 2.92-2.90 (m, 1H), 2.89-2.85 (m, 2H), 2.55 (t, J=7.1Hz, 2H), 2.43-2.31 (m, 2H), 2 .03-1.95(m, 1H), 1.88-1.77(m, 2H), 1.74-1.56(m, 2H), 1.42-1.35(m, 3H), 1.35(s, 9H), 0.89-0.82(m, 6H).

[0448] Step 5: Compound 8-4 (18 mg, 0.02 mmol) was dissolved in DMF (1.5 mL). Eribulin (15 mg, 0.02 mmol) and DIPEA (7 mg, 0.05 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was directly purified by reverse-phase chromatography (ACN / H₂O containing 0.05% TFA = 5%-50%) to obtain the target compound 8-5 (20 mg, 67% yield).

[0449] LCMS (ESI) [M+Na] + =1479.0;

[0450] Step 6: Dissolve compound 8-5 (20 mg, 0.02 mmol) in DCM (8 mL), add TFA (0.4 mL) to the reaction solution, and stir the reaction solution at room temperature for 2 hours. Monitor the reaction by LCMS. The reaction solution is directly purified by reverse phase chromatography (ACN / H2O containing 0.05% TFA = 5%-50%) to obtain the target compound DL008 (12.5 mg, yield 67%).

[0451] LCMS (ESI) [M+Na] + =1379.0;

[0452] 1H NMR (400MHz, DMSO-d6) δ9.99 (s, 1H), 9.11 (s, 2H), 8.15 (d, J = 7.6Hz, 1H), 7.95 (d, J = 8.4Hz , 1H), 7.61 (s, 2H), 7.58-7.52 (m, 2H), 7.28 (d, J=8.5Hz, 2H), 7.07 (t, J=5.3Hz, 1H), 4.99- 4.90(m, 3H), 4.89-4.84(m, 2H), 4.81(s, 1H), 4.75(s, 1H), 4.63-4.57(m, 2H), 4.40-4.32( m, 2H), 4.29 (d, J=9.7Hz, 1H), 4.20 (t, J=7.6Hz, 1H), 4.09-4.02 (m, 1H), 4.03-3.98 (m, 1H) , 3.88-3.72(m, 2H), 3.72-3.68(m, 1H), 3.62-3.58(m, 1H), 3.55-3.51(m, 1H), 3.41(s, 3H) , 3.19 (s, 3H), 3.02-2.94 (m, 4H), 2.80-2.73 (m, 4H), 2.55 (t, J=7.4Hz, 5H), 2.42-2.35 (m, 3H), 2.04-1.90(m, 7H), 1.89-1.78(m, 4H), 1.77-1.67(m, 6H), 1.66-1.59(m, 3H), 1.58-1. 49(m, 4H), 1.48-1.39(m, 5H), 1.36-1.28(m, 5H), 1.04(d, J=6.3Hz, 3H), 0.88-0.84(m, 6H).

[0453] Example 1.9: Preparation of compound DL009

[0454] Step 1: Dissolve compound 9-1 (1.0 g, 1.76 mmol), N-hydroxysuccinimide (0.24 g, 2.11 mmol), and DCC (0.44 g, 2.11 mmol) in DMF (10 mL). Stir and react at 25°C under nitrogen for 16 h. Add methyl tert-ether (50 mL) dropwise to the reaction solution, resulting in the precipitation of a solid. Filtration afforded the target compound 9-2 (1.1 g, 93.9% yield).

[0455] LCMS(ESI)[M-Boc+H] + =565.36.

[0456] Step 2: Compound 9-2 (200 mg, 0.35 mmol) and glycine (52.55 mg, 0.70 mmol) were dissolved in DCM (2 mL) and TEA (70.83 mg, 0.70 mmol) was added. The mixture was stirred at room temperature for 2 h. The reaction mixture was purified by column chromatography (MeOH:DCM = 0%-10%) to obtain the target compound 9-3 (90.0 mg, yield: 47.9%).

[0457] LCMS (ESI) [M+H] + =525.26.

[0458] 1 H NMR (400MHz, DMSO-d6) δ7.95-7.97(m, 1H), 7.88-7.90(m, 2H), 7.72-7.75(m, 2H), 7. 57-7.61 (m, 1H), 7.39-7.43 (m, 2H), 7.30-7.34 (m, 2H), 6.69-6.71 (m, 1H), 4.22-4.30 (m, 4H), 3.96-3.83 (m, 1H), 3.47 (s, 2H), 3.35 (s, 2H), 2.84-2.86 (m, 2H), 1.98-2.03 ( m, 1H), 1.62-1.66 (m, 1H), 1.49-1.50 (m, 1H), 1.36-1.23 (m, 13H), 0.83-0.87 (m, 6H).

[0459] Step 3: Eribulin (25.0 mg, 0.034 mmol), 9-3 (25.49 mg, 0.041 mmol), and HATU (15.51 mg, 0.041 mmol) were dissolved in DMF (1 mL). DIEA (5.27 mg, 0.041 mmol) was added and the mixture was stirred at 25°C under nitrogen for 2 h. The reaction mixture was concentrated and purified by column chromatography (MeOH:DCM = 0%-10%) to obtain the target compound 9-4 (33.0 mg, yield: 72.6%).

[0460] LCMS (ESI) [(M-Boc) / 2+H] + =619.03.

[0461] Step 4: Compound 9-4 (33 mg, 0.025 mmol) was dissolved in DMF (1 mL) and DEA (0.05 mL) and stirred at room temperature for 1 h. THF (10 mL) was added to the reaction solution and concentrated for half an hour to obtain a DMF solution of the target compound 9-5 (27.51 mg).

[0462] LCMS (ESI) [(M-56) / 2+H] +=529.91.

[0463] Step 5: Add 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (8.05 mg, 0.030 mmol), HATU (11.41 mg, 0.030 mmol) and DIEA (9.69 mg, 0.075 mmol) to DMF (1 mL) of compound 9-5 (27.51 mg, 0.025 mmol). Stir the reaction at 25°C under nitrogen for 2 h to obtain a DMF solution of the target compound 9-6 (33.69 mg).

[0464] LCMS (ESI) [(M-Boc) / 2+H] + =633.04.

[0465] Step 6: Compound 9-6 (33.69 mg, 0.025 mmol) in DMF (1 mL) was added with 4 M HCl-DMF (1 mL). The mixture was stirred at room temperature for 1 h. The reaction solution was purified by preparative HPLC (ACN: 0.1% FA in H2O = 10%-50%) to obtain the target compound DL009 (10.0 mg, three-step yield: 31.6%).

[0466] LCMS (ESI) [M / 2+H] + =633.10.

[0467] 1H NMR (400MHz, DMSO-d6) δ9.10 (s, 2H), 8.10-8.00 (m, 2H), 7.89 (d, J=12.0Hz , 1H), 7.69 (t, J=8.0Hz, 1H), 6.73-6.71 (m, 1H), 6.30 (d, J=4.0Hz, 1H), 5.97 (d, J=4.0Hz, 1H), 5.02-4.98(m, 2H), 4.90-4.88(m, 1H), 4.78-4.72(m, 2H), 4.71-4.68(m, 2H), 4.40-4.36(m, 1H), 4.17-4.12(m, 2H), 3.88-3.81(m, 4H) , 3.70-3.60(m, 6H), 3.39(s, 3H), 3.21(s, 3H), 3.12-2.98(m, 3H), 2.89-2. 84(m, 2H), 2.76-2.61(m, 4H), 2.55-2.54(m, 3H), 2.39-2.29(m, 4H), 2.22-2 .20(m, 2H), 2.00-1.94(m, 1H), 1.86-1.89(m, 6H), 1.69-1.45(m, 8H), 1.38- 1.33 (m, 13H), 1.23-1.19 (m, 3H), 0.99 (d, J=4.0Hz, 3H), 0.85-0.81 (m, 6H).

[0468] Example 1.10: Preparation of Compound DL010

[0469] Step 1: Dissolve compound 2-1 (1.0 g, 1.81 mmol) and glycine tert-butyl ester (0.26 g, 1.99 mmol) in DMF (10 mL). Stir at 0°C for 5 minutes, then add DMTMM (0.6 g, 2.17 mmol) and continue the reaction for 1 hour. The reaction solution was diluted with 50 mL of DCM and washed twice with 50 mL of 2% NaHCO₃ water. The organic phase was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by column chromatography (MeOH:DCM = 0-10%) afforded compound 10-2 (1.0 g, yield: 82.98%).

[0470] LCMS (ESI) [M+H] + =665.54;

[0471] Step 2: Compound 10-2 (800.0 mg, 1.2 mmol) was dissolved in DMF (4 mL), and DEA (0.2 mL, 1.94 mmol) was added. The mixture was allowed to react at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was used directly in the next step. The crude product (400.0 mg, 0.9 mmol) and 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (265 mg, 0.99 mmol) were dissolved in DMF (5 mL), stirred at 0°C for 5 minutes, and then DMTMM (274 mg, 0.99 mmol) was added. The reaction mixture was allowed to react for 1 h. The reaction mixture was diluted with 30 mL of DCM and washed twice with 30 mL of 2% NaHCO₃ water. The organic phase was then washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The product was purified by column chromatography (MeOH:DCM = 0-10%) to obtain compound 10-3 (0.3 g, yield: 36.1%).

[0472] LCMS (ESI) [M+H] + =693.56;

[0473] Step 3: Dissolve compound 10-3 (300 mg, 0.43 mmol) in HCl / dioxane (4N, 10 mL) and react at room temperature for 1 h. The reaction solution was concentrated under reduced pressure to obtain the target compound 10-4 (250 mg, yield: 85.8%).

[0474] LCMS (ESI) [M+H] + =637.41;

[0475] Step 4: Compound 10-4 (30.0 mg, 0.045 mmol), eribulin (33 mg, 0.045 mmol), and HATU (18.8 mg, 0.050 mmol) were dissolved in DMF (2 mL). DIPEA (17 mg, 0.14 mmol) was added and allowed to react at room temperature for 1 h. The reaction solution was purified by preparative HPLC (ACN:H2O containing 0.05% FA = 5%-50%) to obtain the target compound DL010 (18 mg, yield: 28.67%).

[0476] LCMS (ESI) [M / 2+H] + =675.47;

[0477] 1H NMR (400MHz, DMSO-d6) δ9.14 (s, 2H), 8.30 (s, 1H), 8.08 (t, J=5.6Hz, 1H), 8.01 (t, J=8.0Hz, 1H), 7.91 (t, J=8.5Hz, 1H), 7.73-7.67 (m, 1H), 5.08 (s, 1H), 5.02 (s, 1H), 4.86 (s, 1H), 4.78 (s, 1H), 4.66 (s, 1H), 4.58 (t, J=4.1Hz, 1H), 4.31-4 .17(m, 4H), 4.13(s, 3H), 4.05(s, 1H), 3.82-3.78(m, 2H), 3.73-3.68(m, 3H), 3. 59-3.50(m, 4H), 3.43(s, 3H), 3.28(s, 3H), 3.16-3.01(m, 3H), 2.89-2.85(m, 1 H), 2.82-2.69(m, 2H), 2.62-2.56(m, 3H), 2.42-2.27(m, 13H), 2.17-2.13(m, 1H ), 2.05-1.91(m, 7H), 1.88-1.79(m, 2H), 1.77-1.61(m, 7H), 1.59-1.45(m, 3H) , 1.41-1.35(m, 9H), 1.31-1.19(m, 3H), 1.05-1.01(m, 4H), 0.89-0.82(m, 12H).

[0478] Example 1.11: Preparation of Compound DL011

[0479] Step 1: Compound 5-1 (500 mg, 1.01 mmol) and 11-1 (265 mg g, 2.02 mmol) were dissolved in DMF. DMTMM (500 mg, 2.02 mmol) was added at 0°C and stirred at room temperature for 2 h. The reaction solution was purified by preparative HPLC (ACN:H2O containing 0.05% FA = 10%-90%) to obtain the target compound 11-2 (62.2 mg, yield: 100%).

[0480] LCMS (ESI) [M+H] + = 609.44

[0481] Step 2: Compound 11-2 (200 mg, 0.33 mmol) was dissolved in DMF (4 mL), and DEA (0.4 mL) was added. The mixture was stirred at room temperature for 1 h. The reaction solution was concentrated under vacuum for 10 min to remove the bulk of DEA. 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (106 mg, 0.40 mmol) and DMTMM (117 mg, 0.40 mmol) were then added. The mixture was stirred at room temperature for 1 h. The reaction solution was purified by liquid chromatography (ACN:H2O containing 0.1% FA = 10%-90%) to afford 11-3 (120 mg, yield: 57.1%).

[0482] LCMS (ESI) [M / 3+1] + =637.41.

[0483] Step 3: Dissolve compound 11-3 (50 mg, 0.079 mmol) in 4M HCl / DMF (2 mL) and stir at room temperature for 1 h. Concentrate the reaction mixture in vacuo and evaporate with DCM (5*3 mL) to obtain 11-4 (45 mg, yield: 92.3%).

[0484] LCMS (ESI) [M+H] + =581.34.

[0485] Step 4: Dissolve 11-4 (32.24 mg, 0.052 mmol), eribulin (29.20 mg, 0.040 mmol), and DMTMM (0.89 mg, 0.0032 mmol) in DMF (1 mL) and stir at room temperature for 1 hour. The reaction mixture was purified by preparative HPLC (ACN:H2O containing 0.1% FA = 10%-90%) to obtain DL011 (11.2 mg, yield: 21.7%).

[0486] LCMS (ESI) [M / 3+1] + =647.44

[0487] 1H NMR (400MHz, DMSO-d6) δ9.15 (s, 2H), 8.28 (s, 1H), 8.11 (t, J=5.7Hz, 1H), 8.06 (d, J=7.5H z, 1H), 7.94 (d, J=8.6Hz, 1H), 7.72 (t, J=5.7Hz, 1H), 5.08 (s, 1H), 5.03 (s, 1H), 4.86 (s, 1H ), 4.78 (s, 1H), 4.69-4.65 (m, 1H), 4.59 (t, J = 4.2Hz, 1H), 4.33-4.27 (m, 1H), 4.26-4.17 ( m, 3H), 4.15-4.11 (m, 3H), 4.09-4.01 (m, 1H), 3.88-3.75 (m, 3H), 3.75-3.67 (m, 4H), 3.63- 3.51 (m, 7H), 3.44 (s, 3H), 3.29 (s, 3H), 3.17-3.10 (m, 2H), 3.09-3.02 (m, 1H), 2.87 (d, J= 10.0Hz, 1H), 2.84-2.67(m, 3H), 2.6-2.57(m, 2H), 2.44-2.36(m, 2H), 2.35-2.27(m, 3H), 2 .26-2.21(m, 3H), 2.15(s, 6H), 2.06-1.92(m, 7H), 1.90-1.79(m, 2H), 1.75-1.64(m, 6H), 1.60-1.50 (m, 2H), 1.43-1.21 (m, 8H), 1.07 (d, J=6.4Hz, 3H), 0.87 (dd, J=8.9, 6.7Hz, 6H).

[0488] Example 1.12: Preparation of Compound DL012

[0489] Step 1: Dissolve compound 12-1 (5.0 g, 50.9 mmol) in toluene (170 mL), add tetrabutylammonium bromide (6.3 g, 19.6 mmol), cool to 0°C, add sodium hydroxide (61.2 g, 535.5 mmol), and then add tert-butyl bromoacetate (34.78 g, 178.32 mmol). React at room temperature overnight. Add water (80 mL) to the reaction solution, then extract three times with EA (80 mL x 3). The combined organic phases are dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain compound 12-2 (10.2 g, 87% yield).

[0490] 1H NMR (400MHz, DMSO-d6) δ8.67 (s, 2H), 3.98 (s, 2H), 3.57 (t, J=6.2Hz, 2H), 2.57-2.54 (m, 2H), 2.52 (s, 3H), 1.83-1.76 (m, 2H), 1.42 (s, 9H).

[0491] Step 2: Compound 12-2 (10 g, 50.5 mmol) was dissolved in THF (100 mL). Compound 12-3 (10.35 g, 50.5 mmol), bistriphenylphosphine palladium dichloride (3.5 g, 5.05 mmol), cuprous iodide (1.92 g, 10.1 mmol), and TEA (15.3 g, 151.5 mmol) were added. The mixture was stirred at 70°C under a nitrogen atmosphere overnight. The reaction mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography (PE:EA = 5:1) to afford compound 12-4 (5.2 g, 31.9% yield).

[0492] LCMS (ESI) [M+H] + =323.0;

[0493] 1 H NMR (400MHz, DMSO-d6) δ8.67 (s, 2H), 3.98 (s, 2H), 3.57 (t, J=6.2Hz, 2H), 2.57-2.54 (m, 2H), 2.52 (s, 3H), 1.83-1.76 (m, 2H), 1.42 (s, 9H).

[0494] Step 3: Dissolve compound 12-4 (1.0 g, 3.1 mmol) in DCM (50 mL), add TFA (3.54 g, 31 mmol), and stir at room temperature overnight. The reaction solution is directly concentrated under reduced pressure to obtain compound 12-5 (1.5 g, crude product).

[0495] LCMS (ESI) [M+H] + =267.0;

[0496] 1 H NMR (400MHz, DMSO-d6) δ8.67 (s, 2H), 4.03 (s, 2H), 3.59 (t, J=6.2Hz, 2H), 2.58-2.53 (m, 2H), 2.53 (s, 3H), 1.84-1.77 (m, 2H).

[0497] Step 4: Compound 12-5 (1.5 g, 5.6 mmol) was dissolved in THF (20 mL) and water (20 mL), and Oxone (10.3 g, 16.8 mmol) was added. The mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to remove THF, and the aqueous phase was extracted three times with EA (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by reverse phase chromatography (ACN / H2O containing 0.05% HCl = 5%-50%) to obtain compound 12-6 (0.4 g, two-step yield: 43.2%).

[0498] LCMS (ESI) [M+H] + =299.1;

[0499] 1 H NMR (400MHz, DMSO-d6) δ12.60 (s, 1H), 9.11 (s, 2H), 4.03 (s, 2H), 3.60 (t, J=6.2Hz, 2H), 3.41 (s, 3H), 2.63 (t, J=7.1Hz, 2H), 1.87-1.80 (m, 2H).

[0500] Step 5: Dissolve compound 12-7 (200.0 mg, 0.53 mmol), 12-6 (158.10 g, 0.53 mmol), and DMTMM (161.33 mg, 0.58 mmol) in DMF (2 mL). Stir and react at 25°C under nitrogen for 2 h. Add DCM (10 mL) to the reaction mixture, and wash the organic phase twice with saturated sodium bicarbonate solution (5 mL x 2). Dry and concentrate to obtain the target compound 12-8 (310 mg, yield: 88.7%).

[0501] LCMS (ESI) [M+H] + =660.45.

[0502] Step 6: Compound 12-8 (310 mg, 0.47 mmol) and p-nitrophenyl chloroformate (189.47 mg, 0.94 mmol) were dissolved in DMF (3 mL) and DIPEA (182.23 mg, 1.41 mmol) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was purified by reverse-phase column chromatography (ACN: 0.1% FA, H2O = 10%-50%) to obtain the target compound 12-9 (120.0 mg, yield: 31.0%).

[0503] LCMS (ESI) [M+H] + =825.46.

[0504] Step 7: Compound 12-9 (80.0 mg, 0.11 mmol) and eribulin (99.81 mg, 0.12 mmol) were dissolved in DMF (1 mL). DIPEA (42.65 mg, 0.33 mmol) was added and the mixture was stirred at 0°C under nitrogen for 2 h. The reaction mixture was concentrated and purified by preparative HPLC (ACN:0.1% TFA, H2O = 10%-60%) to obtain the target compound DL012 (53.0 mg, yield: 77.1%).

[0505] LCMS (ESI) [M / 2+H] + =709.03.

[0506] 1 H NMR (400MHz, DMSO-d6) δ10.03 (s, 1H), 9.10 (s, 2H), 8.33 (d, J = 8.0Hz, 1H), 7.57 (d, J = 8.0Hz, 2H), 7.48 (d, J = 12.0Hz, 1H), 7.27(d, J=8.0Hz, 2H), 7.08-7.06(m, 1H), 5.05-4.93(m, 4H), 4.83-4.75(m, 2H), 4.63-4.54(m, 2H), 4.40-4.25( m, 3H), 4.20-3.96 (m, 8H), 3.83-3.73 (m, 6H), 3.50-3.46 (m, 4H), 3.40 (s, 3H), 3.26-3.22 (m, 4H), 3.04-2.97 (m, 4H), 2.85-2.62(m, 6H), 2.34-2.12(m, 6H), 2.07-1.86(m, 9H), 1.75-1.16(m, 18H), 1.04-0.96(m, 4H), 0.87-0.79(m, 6H).

[0507] Example 1.13: Preparation of Compound DL013

[0508] Step 1: Dissolve compound 13-1 (500.0 mg, 2.11 mmol), 13-2 (388.55 g, 2.11 mmol), and bistriphenylphosphine palladium chloride (148.04 mg, 0.21 mmol) in DMF (2 mL), then add TEA (640.5 g, 6.33 mmol). Stir at 65°C under nitrogen for 3 h. The reaction mixture is concentrated and directly purified by column chromatography (0-50% EA in PE) to obtain the target compound 13-3 (580 mg, yield: 80.8%).

[0509] LCMS (ESI) [M+H] +=341.22.

[0510] Step 2: Compound 13-3 (580.0 mg, 1.70 mmol) was dissolved in DCM (6 mL) and TFA (1 mL) and stirred at room temperature for 2 h; the reaction solution was concentrated and directly purified by column chromatography (0-10% MeOH in DCM) to obtain the target compound 13-4 (250 mg, yield: 51.7%).

[0511] LCMS (ESI) [M+H] + =285.13.

[0512] 1 H NMR (400MHz, DMSO-d6) δ9.11 (s, 2H), 4.10 (s, 2H), 3.71 (t, J=8.0Hz, 2H), 3.41 (s, 3H), 2.84 (t, J=8.0Hz, 2H).

[0513] Step 3: Compound 13-4 (284 mg, 1.0 mmol), DMF (1 mL), and DMTMM-H₂O (295 mg, 1.0 mmol) were added to a reaction flask and stirred at room temperature for 10 min. Compound 12-7 (380 mg, 1.0 mmol) was added and allowed to react for 30 min. The reaction solution was purified by preparative HPLC (ACN:H₂O containing 0.05% HCl = 5%-50%). After lyophilization, the solid was dissolved in 40 mL of DCM and washed once with aqueous sodium bicarbonate solution (30 mL, 2% by weight) and once with 40 mL of water. The mixture was filtered and separated. The filtered solid was mixed with DCM and concentrated under reduced pressure in a 35°C water bath to dryness to obtain the target compound 13-5 (500 mg, yield: 77.4%).

[0514] LCMS (ESI) [M+H] + =646.37;

[0515] Step 4: To a reaction flask were added compound 13-5 (100 mg, 0.15 mmol), DCM (10 mL), bis(p-nitrobenzene) carbonate (137 mg, 0.45 mmol), and TEA (46 mg, 0.45 mmol). The mixture was stirred at 27°C for 16 h. 6 mL of DMF was added, and the DCM was concentrated under reduced pressure on a water bath at room temperature. The mixture was then purified by HPLC (ACN:H2O containing 0.1% FA = 5%-50%) to afford the target compound 13-6 (40 mg, yield: 31.9%).

[0516] LCMS (ESI) [M+H] + =811.59;

[0517] Step 5: To a reaction flask, add DMF (1 mL), compound 13-6 (23.4 mg, 0.029 mmol), eribulin mesylate (20 mg, 0.024 mmol), and DIPEA (9.3 mg, 0.072 mmol). React at room temperature for 1 h. The reaction solution was purified by HPLC (ACN:H2O containing 0.1% FA = 5%-50%) to obtain the target compound DL013 (16 mg, yield: 46.8%).

[0518] LCMS (ESI) [M / 2+H] + =701.48;

[0519] 1 H NMR (400MHz, DMSO-d6) δ10.02 (s, 1H), 9.11 (s, 2H), 8.34 (d, J=7.5Hz, 1H), 7.63-7 .47(m, 3H), 7.34-7.21(m, 2H), 7.07(t, J=5.8Hz, 1H), 5.97(t, J=5.9Hz, 1H), 5.40( s, 2H), 5.08-4.88 (m, 4H), 4.83 (s, 1H), 4.75 (s, 1H), 4.66-4.61 (m, 1H), 4.58-4.50 (m, 2H), 4.45-4.36 (m, 1H), 4.36-4.30 (m, 1H), 4.29-4.22 (m, 1H), 4.21-4.13 (m, 1H ), 4.13-4.07(m, 3H), 4.06-3.97(m, 3H), 3.84-3.64(m, 5H), 3.57-3.45(m, 3H), 3.3 8(s, 3H), 3.31-3.29(m, 1H), 3.27-3.21(m, 4H), 3.07-2.92(m, 4H), 2.90-2.81(m, 3 H), 2.80-2.64(m, 2H), 2.61-2.52(m, 1H), 2.35-2.11(m, 6H), 2.05-1.84(m, 7H), 1. 77-1.12 (m, 17H), 1.08-0.92 (m, 4H), 0.86 (d, J = 6.8Hz, 3H), 0.79 (d, J = 6.8Hz, 3H).

[0520] Example 1.14: Preparation of Compound DL014

[0521] Step 1: Dissolve 14-1 (120 mg, 0.089 mmol) in DMF (2 mL), add DEA (0.2 mL), and stir at room temperature for 2 hours. The reaction solution is diluted with THF and rotary evaporated three times to remove DEA. The resulting DMF solution of 14-2 is used directly in the next reaction.

[0522] LCMS (ESI) [M / 2+H] + =562.42.

[0523] Step 2: To a DMF solution of 14-2 (0.089 mmol, 2 mL) was added 12-5 (31.86 mg, 0.11 mmol). The reaction mixture was cooled to -10°C, and DMTMM (29.55 mg, 0.11 mmol) was added. The reaction mixture was allowed to react at -10°C for 2 hours. After returning to room temperature, the insoluble matter was filtered through a microporous filter membrane. The supernatant was purified by preparative HPLC (ACN:H2O containing 0.05% FA = 5%-50%) to obtain the target compound DL014 (26.7 mg, two-step yield: 21.3%).

[0524] LCMS (ESI) [M / 2+H] + =702.63.

[0525] 1 H NMR (400MHz, DMSO-d6) δ10.03 (s, 1H), 9.10 (s, 2H), 8.33 (d, J=7.4Hz, 1H), 8.28-7.94 (m, 1H), 7.89- 7.54 (m, 3H), 7.47 (d, J = 9.0Hz, 1H), 7.38-7.11 (m, 8H), 5.97 (s, 1H), 5.39 (s, 3H), 5.33 (d, J = 4.9Hz, 1H), 5.15-4.90 (m, 3H), 4.55-4.21 (m, 6H), 4.05-3.90 (m, 6H), 3.61 (t, J=6.2Hz, 3H), 3.39 (s, 3H), 3 .23 (d, J=6.3Hz, 3H), 3.19 (d, J=9.3Hz, 3H), 3.11 (s, 2H), 3.08-2.91 (m, 4H), 2.86 (d, J=14.1Hz, 3H), 2.64(t, J=7.1Hz, 2H), 2.40(d, J=15.8Hz, 1H), 2.31-2.21(m, 1H), 2.15-1.97(m, 4H), 1.87(t , J=6.6Hz, 2H), 1.79-1.67(m, 2H), 1.62-1.40(m, 2H), 1.07-0.97(m, 6H), 0.94-0.72(m, 28H).

[0526] Example 1.15: Preparation of Compound DL015

[0527] Step 1: Compound 5-1 (300 mg, 0.61 mmol), p-aminobenzyl alcohol (150 mg, 0.22 mmol), DCM (1.5 mL), MeOH (0.5 mL), and EEDQ (302 mg, 1.22 mmol) were added to a reaction flask and stirred at 27°C for 16 h. The reaction was monitored by LCMS. The reaction solution was purified by preparative high-performance liquid chromatography (ACN:H2O containing 0.05% HCl = 5%-50%). The prepared solution was adjusted to pH 7-8 using aqueous sodium bicarbonate solution (30 mL, wt = 2%), extracted three times with DCM (30 mL), and the organic phases were combined, dried over anhydrous sodium sulfate for 0.5 h, and concentrated to dryness under reduced pressure in a water bath at 30°C to give the target compound 15-1 (106 mg, yield: 29.2%).

[0528] LCMS (ESI) [M+H] + =601.41

[0529] Step 2: Add compound 15-1 (100 mg, 0.17 mmol), THF (4 mL), and DEA (0.8 mL) to a reaction flask and stir at 27°C for 2 h. Monitor the reaction by LCMS. Concentrate the reaction mixture to dryness under reduced pressure in a 40°C water bath. Dissolve the mixture in DCM (4 mL) and continue concentrating to dryness. Repeat this process once to obtain a concentrated reaction mixture. 12-5 (61 mg, 0.20 mmol) was dissolved in DMF (2 mL), and DMTMM-H2O (60 mg, 0.20 mmol) was added. The mixture was stirred at 27°C for 10 min, and the above reaction solution concentrate was added. The reaction was allowed to react for 30 min. The reaction was monitored by LCMS. The reaction solution was purified by preparative high-performance liquid chromatography (ACN:H2O containing 0.05% HCl = 5%-50%). The prepared solution was adjusted to pH 7-8 using aqueous sodium bicarbonate solution (30 mL, wt = 2%), and extracted four times with DCM (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate for 0.5 h, and concentrated to dryness under reduced pressure at 30°C in a water bath to give the target compound 15-2 (73 mg, yield: 66.6%).

[0530] LCMS (ESI) [M+H] + =659.44

[0531] Step 3: Compound 15-2 (73 mg, 0.11 mmol), DMF (4 mL), di(p-nitrobenzene) carbonate (134 mg, 0.44 mmol), and DIPEA (71 mg, 0.55 mmol) were added to a reaction flask and stirred at 27°C for 16 h. The reaction was monitored by LCMS and purified by HPLC (ACN:H2O containing 0.1% FA = 5%-50%) to give the target compound 15-3 formate salt (50 mg, yield: 51.9%).

[0532] LCMS (ESI) [M+H] + =824.44

[0533] Step 4: DMF (1 mL), compound 15-3 (25 mg, 0.029 mmol), eribulin mesylate (20 mg, 0.024 mmol), and DIPEA (9.3 mg, 0.072 mmol) were added to the reaction flask and reacted at 26° C. for 1 h. The reaction was monitored by LCMS. The reaction solution was purified by HPLC (ACN:H 2 O containing 0.1% TFA = 5%-50%) to obtain the target compound DL015 trifluoroacetate (8 mg, yield: 21.6%).

[0534] LCMS (ESI) [M / 2+H] + =708.18

[0535] 1H NMR (400MHz, DMSO-d6) δ10.08 (s, 1H), 9.30 (s, 1H), 9.13 (s, 2H), 8.38 (d, J=7.5Hz, 1H), 7.60 ( d, J=8.3Hz, 2H), 7.52 (d, J=8.8Hz, 1H), 7.31 (d, J=8.3Hz, 2H), 7.08 (t, J=6.0Hz, 1H), 5.13-5. 05 (m, 1H), 5.04-4.92 (m, 3H), 4.86 (s, 1H), 4.78 (s, 1H), 4.70-4.64 (m, 1H), 4.60-4.56 (m, 1H) , 4.47-4.39(m, 1H), 4.36-4.26(m, 2H), 4.24-4.17(m, 1H), 4.16-4.10(m, 3H), 4.09-4.01(m, 1 H), 3.99 (s, 2H), 3.88-3.75 (m, 2H), 3.75-3.68 (m, 1H), 3.65 (t, J=6.2Hz, 2H), 3.57-3.51 (m, 3 H), 3.30-3.25(m, 4H), 3.07-2.97(m, 4H), 2.90-2.84(m, 1H), 2.81-2.74(m, 7H), 2.70-2.64(m , 2H), 2.63-2.54(m, 3H), 2.36-2.14(m, 6H), 2.08-1.86(m, 10H), 1.82-1.61(m, 9H), 1.58-1.4 6 (m, 3H), 1.39-1.19 (m, 8H), 1.11-0.94 (m, 4H), 0.89 (d, J = 6.8Hz, 3H), 0.83 (d, J = 6.8Hz, 3H).

[0536] Example 1.16: Preparation of Compound DL016

[0537] Step 1: To a reaction flask, add DMF (1 mL), MMAE (20 mg, 0.028 mmol), compound 15-3 (34.02 mg, 0.042 mmol), and DIPEA (6.64 mg, 0.084 mmol). HOBT (5.68 mg, 0.042 mmol) was added with stirring, and the mixture was stirred at room temperature for 4 hours. The reaction solution was purified by HPLC (ACN:H2O containing 0.1% TFA = 10%-60%) to obtain the trifluoroacetic acid salt of the target compound DL016 (3.5 mg).

[0538] LCMS (ESI) [M / 2+H] + =702.09

[0539] 1 H NMR (400MHz, DMSO-d6) δ10.07 (s, 1H), 9.32 (s, 1H), 9.10 (s, 2H), 8.36 (d, J=8. 0Hz, 1H), 8.27-8.25 (m, 1H), 8.04 (d, J=8.0Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 7.62 -7.56 (m, 2H), 7.49 (d, J=8.0Hz, 1H), 7.41-7.17 (m, 7H), 7.19-6.98 (m, 1H), 5.0 6-4.96 (m, 2H), 4.75-6.50 (m, 1H), 4.56-4.35 (m, 3H), 4.31-4.26 (m, 2H), 4.06- 3.92(m, 4H), 3.78-3.76(m, 3H), 3.40(s, 3H), 3.25-3.15(m, 7H), 3.16-2.93(m , 6H), 2.88-2.83(m, 3H), 2.75-2.73(m, 6H), 2.66-2.62(m, 2H), 2.43-2.38(m, 1 H), 2.35-2.19(m, 1H), 2.18-1.91(m, 4H), 1.91-1.84(m, 2H), 1.82-1.57(m, 7H) , 1.57-1.43(m, 2H), 1.40-1.18(m, 4H), 1.11-0.93(m, 7H), 0.92-0.72(m, 25H).

[0540] Example 1.17: Preparation of Compound DL017

[0541] Step 1: Dissolve 17-1 (50.0 mg, 0.098 mmol) in THF (3 mL) and DCM (3 mL), stir at 0°C for 15 min, add p-nitrochloroformic acid phenyl ester (59.26 mg, 0.29 mmol) and TEA (49.58 mg, 0.49 mmol), and stir at 20°C for 3 h. Additional p-nitrochloroformic acid phenyl ester (39.51 mg, 0.20 mmol) and TEA (19.83 mg, 0.20 mmol) are added. The mixture is concentrated under reduced pressure, and the crude product is purified by reverse phase column chromatography (ACN:H2O containing 0.05% formic acid = 10%-90%) to obtain the target compound 17-2 (66.0 mg).

[0542] LCMS (ESI) [M+H] + = 675.33.

[0543] Step 2: Dissolve compound 12-9 (200 mg, 0.24 mmol) in DMF (5 mL), add N-Boc-N,N'-dimethylethylenediamine (50 mg, 0.26 mmol) and DIPEA (37 mg, 0.29 mmol), and react at 18°C ​​for 2 h. The reaction solution was purified by preparative HPLC (ACN:H2O containing 0.05% FA = 5%-50%) to obtain the target compound 17-3 (170 mg).

[0544] LCMS (ESI) [M+H] + = 874.57.

[0545] Step 3: Dissolve TFA (400 μL) in DCM (4 mL), cool to 0°C, add 17-3 (165 mg), and maintain the reaction at 0°C for 2 h. The reaction solution was purified by preparative HPLC (ACN:H2O containing 0.05% FA = 5%-50%) to obtain the formate salt of 17-4 (87 mg).

[0546] LCMS (ESI) [M / 2+H]+ = 387.91.

[0547] 1H NMR (400MHz, DMSO-d6) δ10.14 (s, 1H), 9.13 (s, 2H), 8.42 (d, J=7.4Hz, 1H), 8.33 (s, 1H), 7.67-7.58 (m, 2H), 7.52 (d, J =8.9Hz, 1H), 7.38-7.22(m, 2H), 6.08(t, J=5.8Hz, 1H), 5.47(s, 2H), 5.01(s, 2H), 4.46-4.37(m, 1H), 4.37-4.30(m, 1H ), 3.98 (s, 2H), 3.64 (t, J = 6.2Hz, 2H), 3.47-3.36 (m, 5H), 3.10-2.94 (m, 2H), 2.93-2.79 (m, 5H), 2.66 (t, J = 7.1Hz, 2H ), 2.52-2.37(m, 5H), 2.08-1.98(m, 1H), 1.95-1.85(m, 2H), 1.78-1.55(m, 2H), 1.53-1.29(m, 2H), 0.95-0.75(m, 6H).

[0548] Step 4:

[0549] Reagent 17-4 (61.0 mg, 0.074 mmol) was dissolved in DCM (5 mL) and DMF (0.5 mL), and 17-2 (50.0 mg, 0.074 mmol) and TEA (22.0 mg, 0.22 mmol) were added. The mixture was stirred at 20°C for 2 h, and concentrated under reduced pressure. The crude product was purified by preparative HPLC (ACN:H2O containing 0.1% formic acid = 10%-90%) to obtain the target compound DL017 (46.9 mg).

[0550] LCMS (ESI) [M+H] + = 1309.74.

[0551] 1H NMR (400MHz, DMSO-d6) δ11.59 (d, J=11.8Hz, 1H), 10.03 (d, J=12.2Hz, 1H), 9.10 (s, 2H), 8.36 (d, J=7.2 Hz, 1H), 8.29 (s, 1H), 8.08 (dt, J=9.1, 4.7Hz, 1H), 7.50 (qd, J=17.8, 16.3, 9.3Hz, 4H), 7.39 (d, J=8.9H z, 1H), 7.28 (dd, J=40.9, 8.1Hz, 2H), 7.17 (d, J=2.4Hz, 1H), 7.07 (d, J=7.3Hz, 1H), 6.91 (dd, J=8.9, 2. 3Hz, 1H), 6.00 (t, J=5.8Hz, 1H), 5.42 (s, 2H), 5.03 (s, 1H), 4.98 (d, J=7.6Hz, 1H), 4.72 (q, J=8.3, 6.5Hz , 1H), 4.67-4.57 (m, 1H), 4.38 (s, 1H), 4.31 (d, J=7.1Hz, 2H), 4.08 (t, J=6.0Hz, 2H), 3.96 (s, 3H), 3.69 (d, J=8.8Hz, 2H), 3.60 (d, J=6.2Hz, 2H), 3.39 (m, 6H), 3.12 (s, 2H), 3.02 (d, J=10.0Hz, 2H), 2.99-2.89 (m, 4H), 2.87 (d, J=3.9Hz, 2H), 2.82 (t, J=5.9Hz, 2H), 2.63 (t, J=7.1Hz, 2H), 2.57 (s, 3H), 2.56 (s, 2H) , 2.00 (dt, J=13.2, 6.5Hz, 1H), 1.87 (p, J=6.9Hz, 2H), 1.77-1.19 (m, 8H), 0.83 (dd, J=24.0, 6.6Hz, 6H).

[0552] 2. Preparation of Multi-Warhead Antibody-Drug Conjugates

[0553] Example 2.1: Preparation of HER2-ADC-001

[0554] A total of 12.55 mg of trastuzumab was added to a 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.5 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and incubated at 25°C for 90 minutes. Six times the molar equivalent of the antibody (10 mmol / L) of DL003 dissolved in DMSO and three times the molar equivalent of DL001 dissolved in DMSO were mixed thoroughly and added to the antibody. After mixing, the solution was incubated at 25°C for 2 hours to obtain the conjugated sample. After completion of the reaction, the sample was exchanged into a 20 mM histidine buffer (pH 6.0) using a 30 kDa ultrafiltration tube to remove low-molecular-weight substances. The sample was then concentrated to obtain HER2-ADC-001.

[0555] RP-LC / MS was used to determine the DAR value of the coupled sample.

[0556] LC / MS Model:

[0557] Liquid phase parameters

[0558] Mass spectrometry results showed that the HER2-ADC-001 sample's light chain was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, and DAR1-DL001 ratios were 18.2%, 55.3%, and 26.4%, respectively), and the heavy chain was conjugated to 0-3 toxin molecules (HC, DAR1, DAR2, DAR3-2*DL003-DL001, DAR3-DL003-2*DL001, DAR3-3*DL003, and DAR3-3*DL001 ratios were 0%, 0%, 0%, 16.2%, 2.5%, 70.0%, and 11.2%, respectively). Based on this, the HER2-ADC-001 sample's conjugation ratio (DAR value) was calculated to be 7.6, indicating that each mole of antibody was conjugated to 6.00 moles of DL003 and 1.62 moles of DL001, respectively. This means that n1 = 6.00 and n2 = 1.62.

[0559] Example 2.2: Preparation of HER2-ADC-002

[0560] Method 1: Add 6.28 mg of trastuzumab to a final concentration of 1 mM sodium edetate solution and mix well. Adjust the sample pH to 7.45 with 0.5 M disodium hydrogen phosphate solution; add 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody), mix well, and let it stand at 30°C for 90 minutes; take 10 mmol / L DL003 (5.5 times the molar equivalent of the antibody) dissolved in DMSO and 10 mmol / L DL007 (3.5 times the molar equivalent of the antibody) dissolved in DMSO, mix well, add to the above antibodies, mix well, and let it stand at 30°C for 3 hours to obtain the conjugated sample HER2-ADC-002.

[0561] Using the mass spectrometry detection method of Example 2.1, the results showed that the light chain of the HER2-ADC-002 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL007 ratios were 13.3%, 47.6%, and 39.1%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL007, DAR3-DL003-2*DL007, DAR3-3*DL003, and DAR3-3*DL007 ratios were 22.2%, 1.2%, 54.2%, and 22.5%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-002 sample was calculated to be 7.7, and each mole of antibody was conjugated to 5.1 moles of DL003 and 2.6 moles of DL007, respectively. That is, n1 = 5.1, n3 = 2.6.

[0562] Method 2: Add 6.28 mg of trastuzumab to a final concentration of 1 mM sodium edetate solution and mix well. Adjust the sample pH to 7.45 with 0.5 M disodium hydrogen phosphate solution; add 20 mmol / L TCEP solution with a 5.5-fold molar equivalent of the antibody, mix well, and incubate at 30°C for 90 minutes; first add 10 mmol / L DL003 dissolved in DMSO with a 5.5-fold molar equivalent of the antibody, and after 1 hour of reaction, add 10 mmol / L DL007 dissolved in DMSO with a 3.5-fold molar equivalent of the antibody. After 2 hours of reaction, the conjugated sample HER2-ADC-002 is obtained.

[0563] Using the mass spectrometry detection method of Example 2.1, the results showed that the light chain of the HER2-ADC-002 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, and DAR1-DL007 in ratios of 12%, 50.2%, and 37.8%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL007, DAR3-DL003-2*DL007, DAR3-3*DL003, and DAR3-3*DL007 in ratios of 5%, 0%, 66%, and 29%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-002 sample was calculated to be 7.8, and each mole of antibody was conjugated to 5.2 moles of DL003 and 2.6 moles of DL007, respectively. That is, n1 = 5.2, n3 = 2.6.

[0564] Example 2.3: Preparation of HER2-ADC-003

[0565] A total of 25.1 mg of trastuzumab was added to a 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.47 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and incubated at 30°C for 90 minutes. A 10 mmol / L DL003 solution (6.2 times the molar equivalent of the antibody) dissolved in DMSO was added. After a 1-hour reaction, a 10 mmol / L DL007 solution (3.0 times the molar equivalent of the antibody) dissolved in DMSO was added. After a 2-hour reaction, excess cysteine ​​was added. The sample was designated HER2-ADC-003. The buffer was exchanged with a 20 mM His-HCl buffer solution at pH 5.9 using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The HER2-ADC-003 sample was then sampled for DAR analysis.

[0566] The results showed that the light chain of the HER2-ADC-003 sample was conjugated to 0-1 toxin molecules (LC, DL003, DAR1-DL007 in the ratios of 7.6%, 56.9%, and 35.5%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL007, DAR3-DL003-2*DL007, DAR3-3*DL003, and DAR3-3*DL007 in the ratios of 14.9%, 8.2%, 67.4%, and 9.5%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-003 sample was calculated to be 7.8, and each mole of antibody was conjugated to 5.9 moles of DL003 and 1.9 moles of DL007, respectively. That is, n1 = 5.9, n3 = 1.9.

[0567] Example 2.4: Preparation of HER2-ADC-004

[0568] A total of 14.0 mg of trastuzumab was added to a 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.47 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and incubated at 25°C for 90 minutes. A 10 mmol / L DMSO solution (4.2 times the molar equivalent of the antibody) of DL007 and a 10 mmol / L DMSO solution (4.5 times the molar equivalent of the antibody) of DL002 were added to the antibody solution. The mixture was then added to the antibody solution and incubated at 25°C for 2 hours. The buffer was then exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) with a 20 mM His-HCl buffer solution at pH 5.9 to obtain the conjugated sample, Her2-ADC-004.

[0569] Mass spectrometry results showed that the light chain of Her2-ADC-004 sample was conjugated to 0 to 1 toxin molecules (LC, DAR1-DL002, DAR1-DL007 ratios were (8.4%, 47.7%, 43.9%), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL002-DL007, DAR3-DL002-2*DL007, DAR3-3*DL002, DAR3-3*DL007, DAR2- The ratios of 2*DL002, DAR2-2*DL007, and DAR2-DL002-DL007 were 34.2%, 28.5%, 22.0%, 13.6%, 0.5%, 0.5%, and 0.6%, respectively. Based on this, the coupling ratio (DAR value) of the Her2-ADC-004 sample was calculated to be 7.8, and each mole of antibody was conjugated to 4.3 moles of DL002 and 3.5 moles of DL007. (n2 = 4.3, n3 = 3.5).

[0570] Example 2.5: Preparation of HER2-ADC-005

[0571] To 0.5 mL of trastuzumab (12.35 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.56 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. A 6.0-fold molar equivalent of the mixed antibody (10 mmol / L) of DL003 dissolved in DMSO and a 5-fold molar equivalent of the antibody (10 mmol / L) of DL012 dissolved in DMSO were added. The mixture was reacted at 25°C for 2 hours, followed by addition of excess cysteine. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) with a 20 mM His-HCl buffer solution at pH 5.9 to obtain a HER2-ADC-005 sample, which was then sampled for detection of the DAR value.

[0572] The results showed that the light chain of the HER2-ADC-005 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL012 ratios were (3.8%, 65.7%, and 30.6%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL012, DAR3-DL003-2*DL012, DAR3-3*DL003, and DAR3-3*DL012 ratios were 24.5%, 4.8%, 66.5%, and 4.2%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-005 sample was calculated to be 7.9, and each mole of antibody was conjugated to 6.38 moles of DL003 and 1.54 moles of DL012, respectively. n1 = 6.38, n2 = 1.54.

[0573] Example 2.6: Preparation of HER2-ADC-006

[0574] To 0.5 mL of trastuzumab (12.35 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.56 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. 10 mmol / L DL003 (7.0 times the molar equivalent of the antibody) dissolved in DMSO and 10 mmol / L DL012 (4 times the molar equivalent of the antibody) dissolved in DMSO were added. The mixture was reacted at 25°C for 2 hours, followed by addition of excess cysteine. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) with a 20 mM His-HCl buffer solution at pH 5.9 to obtain a HER2-ADC-006 sample, which was then sampled for detection of the DAR value.

[0575] The results showed that the light chain of the HER2-ADC-006 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL012 ratios were (2.7%, 77.7%, and 19.5%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL012, DAR3-DL003-2*DL012, DAR3-3*DL003, and DAR3-3*DL012 ratios were 23.2%, 2.6%, 74.3%, and 0.0%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-006 sample was calculated to be 7.9, and each mole of antibody was conjugated to 6.99 moles of DL003 and 0.96 moles of DL012, respectively. n1 = 6.99, n2 = 0.96.

[0576] Example 2.7: Preparation of HER2-ADC-007

[0577] To 0.6 mL of trastuzumab (14.82 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.44 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. 10 mmol / L DL003 (5.6 times the molar equivalent of the antibody) dissolved in DMSO and 10 mmol / L DL012 (2 times the molar equivalent of the antibody) dissolved in DMSO were added. The mixture was reacted at 25°C for 2 hours, followed by addition of excess cysteine. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The buffer was replaced with a 20 mM His-HCl buffer solution at pH 5.9 to obtain a HER2-ADC-007 sample, which was then sampled for detection of the DAR value.

[0578] The results showed that the light chain of the HER2-ADC-007 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL012 ratios were (11.3%, 59.3%, and 29.4%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL012, DAR3-DL003-2*DL012, DAR3-3*DL003, and DAR3-3*DL012 ratios were 16.8%, 2.0%, 65.8%, and 15.4%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-007 sample was calculated to be 7.8, and each mole of antibody was conjugated to 5.85 moles of DL003 and 1.93 moles of DL012, respectively. n1 = 5.85, n2 = 1.93.

[0579] Example 2.8: Preparation of HER2-ADC-008

[0580] 0.7 mL of trastuzumab (17.29 mg) was added to a final concentration of 1 mM sodium edetate solution and mixed. The pH of the sample was adjusted to 7.37 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. DL003 (0.073 mg) dissolved in DMSO (4.7 times the molar equivalent of the antibody) and DL012 (0.087 mg) dissolved in DMSO (10 mmol / L) were added, and the mixture was reacted at 25°C for 2 hours. Excess cysteine ​​was added, and the solution was replaced with a 20 mM His-HCl buffer solution at pH 5.9 using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The HER2-ADC-008 sample was obtained, and the DAR value was detected by sampling.

[0581] The results showed that the light chain of the HER2-ADC-008 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL012 ratios were (0.0%, 36.0%, 64.0%), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL012, DAR3-DL003-2*DL012, DAR3-3*DL003, DAR3-3*DL012 ratios were 23.9%, 7.4%, 48.8%, and 19.9%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-008 sample was calculated to be 8.0, and each mole of antibody was conjugated to 4.75 moles of DL003 and 3.25 moles of DL012, respectively. n1 = 4.75, n2 = 3.25.

[0582] Example 2.9: Preparation of HER2-ADC-009

[0583] 0.7 mL of trastuzumab (17.29 mg) was added to a final concentration of 1 mM sodium edetate solution and mixed. The pH of the sample was adjusted to 7.37 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. DL003 (0.084 mg) dissolved in DMSO (5.4 times the molar equivalent of the antibody) and DL012 (0.077 mg) dissolved in DMSO (10 mmol / L) (4.0 times the molar equivalent of the antibody) were added. The mixture was reacted at 25°C for 2 hours, and then excess cysteine ​​was added. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The buffer was replaced with a 20 mM His-HCl buffer solution at pH 5.9 to obtain a HER2-ADC-009 sample, which was then sampled for detection of the DAR value.

[0584] The results showed that the light chain of the HER2-ADC-009 sample was conjugated to 0-1 toxin molecules (LC, DAR1-DL003, DAR1-DL012 ratios were (2.5%, 48.4%, 49.1%), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL012, DAR3-DL003-2*DL012, DAR3-3*DL003, DAR3-3*DL012 ratios were 21.5%, 7.8%, 57.1%, and 13.6%, respectively). Based on this, the coupling ratio (DAR value) of the HER2-ADC-009 sample was calculated to be 7.9, and each mole of antibody was conjugated to 5.41 moles of DL003 and 2.54 moles of DL012, respectively. n1 = 5.41, n2 = 2.54.

[0585] Example 2.10: Preparation of HER2-ADC-010

[0586] To 0.8 mL of trastuzumab (19.76 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.43 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. A 6.0-fold molar equivalent of the mixed antibody (10 mmol / L) of DL003 dissolved in DMSO and a 4.0-fold molar equivalent of the antibody (10 mmol / L) of DL014 dissolved in DMSO were added. The mixture was reacted at 25°C for 2 hours, followed by addition of excess cysteine. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The buffer was replaced with a 20 mM His-HCl buffer solution at pH 5.9 to obtain a HER2-ADC-010 sample, which was then sampled for detection of the DAR value.

[0587] The results showed that the HER2-ADC-010 sample had 0-1 toxin molecules conjugated to the light chain (LC, DAR1-DL003, and DAR1-DL014 ratios were 1.0%, 53.9%, and 45.1%, respectively), and the heavy chain was conjugated to 3 toxin molecules (DAR3-2*DL003-DL014, DAR3-DL003-2*DL014, DAR3-3*DL003, and DAR3-3*DL014 ratios were 11.9%, 2.6%, 70.0%, and 15.6%, respectively). Based on this, the HER2-ADC-010 sample coupling ratio (DAR value) was calculated to be 8.0, and each mole of antibody was conjugated to 5.8 moles of DL003 and 2.2 moles of DL014, respectively. (n1 = 5.8, n3 = 2.2).

[0588] Example 2.11: Preparation of HER2-ADC-011

[0589] 12.35 mg of trastuzumab (0.5 mL) was added to a final concentration of 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.5 with 0.5 M sodium hydrogen phosphate solution. A 5.5-fold molar equivalent of the antibody in a 20 mmol / L TCEP solution was added, mixed thoroughly, and allowed to stand at 25°C for 90 minutes. A 3.0-fold molar equivalent of the antibody (10 mmol / L) of DL003 dissolved in DMSO and a 1.6-fold molar equivalent of the antibody (10 mmol / L) of DL014 dissolved in DMSO were added to the mixture. The mixture was reacted at 25°C for 2 hours, after which excess cysteine ​​was added. The solution was exchanged with a 20 mM His-HCl buffer solution at pH 5.9 using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) to obtain the HER2-ADC-011 sample. The DAR values ​​were determined: 3.0 mol of DL003 and 0.9 mol of DL014 were conjugated to each mol of antibody. n1 = 3.0, n3 = 0.9.

[0590] Example 2.12: Preparation of HER2-ADC-012

[0591] 12.35 mg of trastuzumab (0.5 mL) was added to a final concentration of 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.5 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and allowed to stand at 25°C for 90 minutes. DL003 (10 mmol / L) dissolved in DMSO (4.0 times the molar equivalent of the antibody) and DL014 (10 mmol / L) dissolved in DMSO (1.6 times the molar equivalent of the antibody) were added to the mixture. The mixture was reacted at 25°C for 2 hours, after which excess cysteine ​​was added. The solution was exchanged with a 20 mM His-HCl buffer solution (pH 5.9) using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) to obtain the HER2-ADC-012 sample. The DAR values ​​were determined: 4.1 moles of DL003 and 1.3 moles of DL014 were conjugated to each mole of antibody. (n1 = 4.1, n3 = 1.3)

[0592] Example 2.13: Preparation of HER2-ADC-013

[0593] 12.35 mg of trastuzumab (0.5 mL) was added to a final concentration of 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.5 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and allowed to stand at 25°C for 90 minutes. DL003 (10 mmol / L) dissolved in DMSO (6.1 times the molar equivalent of the antibody) and DL012 (10 mmol / L) dissolved in DMSO (2.5 times the molar equivalent of the antibody) were added to the mixture. The mixture was reacted at 25°C for 2 hours, after which excess cysteine ​​was added. The solution was exchanged with a 20 mM His-HCl buffer solution (pH 5.9) using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) to obtain a HER2-ADC-013 sample. The DAR values ​​were determined: 4.7 moles of DL003 and 0.9 moles of DL012 were conjugated to each mole of antibody, respectively. (n1 = 4.7, n2 = 0.9).

[0594] Example 2.14: Preparation of HER2-ADC-014

[0595] To 0.4 mL of trastuzumab (11.52 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.45 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.75 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. First, 10 mmol / L DL003 (6.8 times the molar equivalent of the antibody) dissolved in DMSO was added and reacted at 25°C for 2 hours. Then, 10 mmol / L DL017 (3 times the molar equivalent of the antibody) dissolved in DMSO was added and reacted at 25°C for 4 hours. After that, excess cysteine ​​was added and the solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The buffer was replaced with a 20 mM His-HCl buffer solution at pH 5.98 to obtain the HER2-ADC-014 sample. The DAR value was detected by sampling: each mole of antibody was conjugated to 7.2 moles of DL003 and 0.8 moles of DL017. n1=7.2, n2=0.8.

[0596] Example 2.15: Preparation of HER2-ADC-015

[0597] To 0.4 mL of trastuzumab (11.52 mg), a final concentration of 1 mM sodium edetate solution was added and mixed. The pH of the sample was adjusted to 7.45 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.75 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. First, 10 mmol / L DL003 (6.2 times the molar equivalent of the antibody) dissolved in DMSO was added and reacted at 25°C for 2 hours. Then, 10 mmol / L DL017 (3 times the molar equivalent of the antibody) dissolved in DMSO was added and reacted at 25°C for 4 hours. After addition of excess cysteine, the solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) with a 20 mM His-HCl buffer solution at pH 5.98 to obtain the HER2-ADC-015 sample. The DAR value was measured: each mole of antibody was conjugated to 7.0 moles of DL003 and 1.0 mole of DL017. n1=7.0, n2=1.0.

[0598] Example 2.16: Preparation of B7H3-ADC-001

[0599] The B7H3 antibody (2E3-02) was added to a final concentration of 17.2 mg / mL, a total of 342.71 mg, and a sodium edetate solution was added to a final concentration of 1 mM, and the pH of the sample was adjusted to 7.5 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. A mixture of DL003 (6.0 times the molar equivalent of the antibody) and DL014 (2.05 times the molar equivalent of the antibody) dissolved in DMSO (0.680 g) was added, and the mixture was reacted at 25°C for 4 hours. Excess cysteine ​​was added, and the solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). The buffer was replaced with a 20 mM His-HCl buffer solution at pH 5.98 to obtain the B7H3-ADC-001 sample. The DAR value was detected: 5.96 moles of DL003 and 1.82 moles of DL014 were conjugated to each mole of antibody. n1=5.96, n3=1.82.

[0600] Example 2.17: Preparation of B7H3-ADC-002

[0601] The B7H3 antibody (2E3-02) was added to a final concentration of 17.2 mg / mL, a total of 345.01 mg, with sodium edetate solution added to a final concentration of 1 mM and mixed. The pH of the sample was adjusted to 7.5 with 0.5 M disodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed, and allowed to stand at 25°C for 90 minutes. A mixture of DL003 (6.25 times the molar equivalent of the antibody) dissolved in DMSO and DL014 (2.14 times the molar equivalent of the antibody) dissolved in DMSO (0.714 g) was added. The mixture was reacted at 25°C for 4 hours, after which excess cysteine ​​was added. The solution was exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15) with a 20 mM His-HCl buffer solution at pH 5.98 to obtain a B7H3-ADC-002 sample. The DAR value was determined as follows: 6.21 moles of DL003 and 1.77 moles of DL014 were conjugated to each mole of antibody. n1=6.21, n3=1.77.

[0602] Example 2.18: Preparation of B7H3-ADC-003

[0603] A total of 339.44 mg of the B7H3 antibody (2E3-02) at a concentration of 17.2 mg / mL was added to a 1 mM sodium edetate solution and mixed thoroughly. The pH of the sample was adjusted to 7.5 with 0.5 M sodium hydrogen phosphate solution. A 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody) was added, mixed thoroughly, and incubated at 25°C for 120 minutes. DL003 (10 mmol / L) dissolved in DMSO (6.03 times the molar equivalent of the antibody) was added first, reacted at 25°C for 1 hour, and then DL014 (10 mmol / L) dissolved in DMSO (3.0 times the molar equivalent of the antibody) was added. The reaction was incubated at 25°C for 180 minutes before excess cysteine ​​was added to obtain the B7H3-ADC-003 sample. The DAR values ​​were determined: 6.0 mol of DL003 and 1.99 mol of DL014 were conjugated to each mol of antibody. n1 = 6.01, n3 = 1.99.

[0604] 3. Preparation of Monotoxin Antibody Drug Conjugates

[0605] Example 3.1 Preparation of HER2-DL012-DAR2

[0606] To 0.4 mL of trastuzumab (9.88 mg), add sodium edetate solution with a final concentration of 1 mM and mix well. The sample pH is adjusted to 7.45 with 0.5 M disodium hydrogen phosphate solution. Add 20 mmol / L TCEP solution (5.5 times the molar equivalent of the antibody), mix well, and incubate at 25°C for 90 minutes. Add 10 mmol / L DL012 (0.055 mg) dissolved in DMSO (5.0 times the molar equivalent of the antibody), react at 25°C for 2 hours, then add excess cysteine. The solution is exchanged using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15), and the buffer is replaced with 20 mM His-HCl buffer solution at pH 5.9 to obtain the HER2-DL012-DAR2 sample with a DAR value of 1.8.

[0607] Example 3.2 Preparation of HER2-DL003-DAR8

[0608] 5.0 mL of trastuzumab (16.1 mg / mL) was diluted with 0.10 mL of 20 mM PB + 100 mM edetate disodium solution (pH 7.6), and the pH was adjusted to 7.46 with 0.5 M Na2HPO4 solution. 1.0 mL of this solution was added to 20 mM TCEP (0.0278 mL, 0.556 μmol), mixed, and allowed to stand at room temperature for 90 minutes. A solution of DL003 (1.332 mg, 10 times the molar amount of the antibody) in DMSO (0.1213 mL) was then added, mixed, and allowed to stand at room temperature for 2 hours. After completion, the solution was exchanged with a 20 mM His-HCl buffer solution at pH 5.9 using a centrifugal ultrafiltration tube (Merck, Amicon Ultra-15). This yielded HER2-DL003-DAR8, with a DAR value of 8.0.

[0609] IV. In vitro cell activity testing of antibody-drug conjugates (ADCs)

[0610] Example 4.1: Testing of ADC's proliferation inhibitory activity against N87 tumor cells

[0611] Experimental methods

[0612] Resuscitated N87 (1640 + 10% FBS) cells were plated in a 96-well flat-bottom plate at a density of 5000 / well and 100ul / well and cultured in a 37°C incubator overnight. The next day, the ADC molecule to be tested was diluted with complete culture medium to a maximum concentration of 1000nM, and 10 points were diluted 4-fold. 100ul of diluted ADC-003 was added to the cell culture wells (2 parallels per well). After culturing at 37°C for 4 days, 50ul of Cell titer glo substrate was added to each well, and the fluorescence value was detected after incubation for 5 minutes. Among them, the sources of key materials are shown in Table 1 below:

[0613] Table 1 Material sources

[0614] Experimental results:

[0615] Table 2 ADC inhibitory activity on N87 tumor cell proliferation in vitro

[0616] As shown in Table 2, the multi-warhead ADC molecules disclosed herein all have significant proliferation inhibitory activity on the N87 tumor cell line.

[0617] Example 4.2: In vitro proliferation inhibition activity of multi-bullet ADCs against various human tumor cell lines

[0618] Experimental methods

[0619] The cell growth inhibitory activity of multi-bullet ADCs was assessed using the HER2-overexpressing cell line SKBR3 and the HER2-low-expressing cell lines H358 and MCF7. H358 (RPMI1640 + 10% FBS), SKBR3 (RPMI1640 + 10% FBS), and MCF7 (DMEM + 10% FBS + 5 μg / ml insulin) tumor cells were cultured according to standard procedures at 37°C, 5% CO2 in a humidified incubator using the designated cell culture medium. H358, SKBR3, and MCF7 tumor cells were digested using trypsin using standard procedures, harvested, and counted. Cells were resuspended in the corresponding complete culture medium and 5,000 cells / well were plated onto a 96-well plate at 100 μl per well. Test drugs were diluted in complete culture medium: the multi-bullet ADC concentration was initially 2,000 nM and diluted 4-fold to 10 concentration points. A total of 100 μl of diluted ADC was added to a 96-well plate containing 100 μl of culture medium and cells and incubated at 37°C, 5% CO2 for 4 days. After the incubation, 50 μl of cell titer glow substrate was added to each cell well and incubated at room temperature for 5 minutes before the full wavelength fluorescence value was measured. GraphPad software was used to plot the dose-dependent cell proliferation inhibition graph and analyze the half-maximal inhibitory concentration (IC 50 , nM). The sources of key materials are shown in Table 3 below:

[0620] Table 3 Material sources

[0621] 2. Experimental results

[0622] Table 4 Inhibitory activity of ADC on proliferation of various tumor cells in vitro

[0623] Note: “ / ” means not tested

[0624] As shown in Table 4, the multi-warhead ADC molecules disclosed herein have significant proliferation inhibitory activity on tumor cell lines with high or low HER2 expression.

[0625] Example 4.3: In vitro proliferation inhibition assay of multi-warhead ADCs against N87 cells overexpressing ABCB1 / ABCG2 transporters

[0626] 1. Experimental methods

[0627] The proliferation inhibitory activity of multi-warhead ADCs and single-toxin ADCs was detected using N87 cells (ATCC, modified by WuXi AppTec) overexpressing human ABCB1 or human ABCG2. N87 tumor cells overexpressing human ABCB1 and human ABCG2 were cultured in a 37°C, 5% CO2 incubator and cell-specific culture medium (RPMI1640 + 10% FBS) according to conventional methods. Tumor cells were digested using trypsin by conventional methods, and the cells were collected and counted. The cells were resuspended in the corresponding complete culture medium and 3000 cells / well were added to a 96-well plate at 100ul / well. Preparation of ADC sample concentration gradient: Use complete culture medium to dilute the drug to be tested. For human ABCB1 overexpressing N87 cells, the concentration of each ADC drug starts from 2000nM and is diluted 5-fold for 10 concentration points; for human ABCG2 overexpressing N87 cells, HER2-DL003-DAR8 starts from 2000nM and is diluted 5-fold for 10 concentration points. Other ADC drugs are diluted from 200nM for 10 concentration points. A total of 100uL of diluted ADC is added to a 96-well plate containing 100ul of culture medium and cells, and cultured in a 37°C 5% CO2 incubator for 6-7 days (7 days for toxin and 6 days for ADC). After incubation, 75ul of cell titer glow substrate is added to each cell well, and the full-wavelength fluorescence value is detected after incubation at room temperature for 10 minutes. GraphPad software is used to draw a dose-dependent cell proliferation inhibition graph and analyze its half-maximal inhibitory concentration (IC 50 , nM).

[0628] 2. Experimental results

[0629] Table 5 In vitro proliferation inhibition activity of ADC on transporter-overexpressing tumor cells

[0630] HER2-DL012-DAR2 (a single toxin ADC) lost activity in human ABCB1-overexpressing N87 tumor cells, and HER2-DL003-DAR8 (a single toxin ADC) lost activity in human ABCG2-overexpressing N87 cells. However, the multi-warhead ADC molecules retained good activity in both of these transporter-overexpressing cells (as shown in Table 5). This shows that the multi-warhead ADCs disclosed herein can overcome the drug resistance issues of single-warhead ADCs.

[0631] Example 4.4: Detection of the Inhibitory Activity of Multi-Warhead ADCs on Enhertu-Resistant NCI-N87 Tumor Cells in Vitro

[0632] 1. Experimental methods:

[0633] NCI-N87 tumor cells resistant to Enhertu (RPMI 1640 + 10% FBS + 1 μg / mL puromycin + 100 ng / ml Enhertu) (modified by WuXi AppTec) were revived and cultured, plated in 96-well flat-bottom plates at a density of 2E4 / well, 135 μL / well, and cultured in a 37 ° C incubator overnight. The next day, the ADC molecule to be tested was diluted with serum-free culture medium to a maximum final concentration of 300nM, 4-fold dilution, and a total of 9 points. Add 15 μL of diluted ADC sample (10*) to the cell culture wells. After culturing at 37 ° C for 6 days, 75 μL CellTiter-Glo substrate was added to each well, and the cell plate was wrapped with aluminum foil to avoid light. The culture plate was shaken on an orbital shaker for 2 minutes to induce cell lysis. The culture plate was placed at room temperature for 10 minutes to stabilize the luminescent signal, and then the luminescent signal was detected on a 2104 EnVision plate reader.

[0634] 2. Experimental results:

[0635] Table 6 In vitro proliferation inhibitory activity of ADC against Enhertu-resistant NCI-N87 tumor cells

[0636] As shown in Table 6, the dual-toxin ADC molecules disclosed herein have significant proliferation inhibitory activity on Enhertu-resistant NCI-N87 tumor cells. As shown in Figure 1, the dual-toxin ADC molecules disclosed herein have a significantly higher inhibition rate on Enhertu-resistant NCI-N87 tumor cells than the single-toxin ADC molecules.

[0637] 5. In vivo tumor activity testing of antibody-drug conjugates (ADCs)

[0638] Example 5.1 Efficacy testing of multi-bullet ADCs on NCI-H358 transplanted tumors

[0639] 1. Experimental Materials

[0640] Investigational drug: HER2-ADC-007

[0641] Negative control: normal saline

[0642] Experimental cells: NCI-H358 human non-small cell lung cancer cells, purchased from ATCC;

[0643] Experimental animals: Balb / c nude mice, female, 5-6 weeks old, were purchased from Chengdu Yaokang Biotechnology Co., Ltd.

[0644] 2. Experimental Methods

[0645] Cell treatment

[0646] NCI-H358 cells were cultured in 15 cm diameter culture dishes using 1640 medium containing 10% FBS. When the cells reached 80-90% confluency, they were digested with trypsin-EDTA, washed twice with PBS, and then centrifuged and resuspended in pre-cooled PBS. The cells were counted using a cell counter and diluted with PBS to a cell concentration of 5 × 10 7 / ml.

[0647] 2.2. Tumor cell transplantation

[0648] Balb / c nu mice were acclimated to the laboratory environment for 3-5 days and inoculated subcutaneously with 5×10 NCI-H358 cells in the right rib cage. 6 / mouse, the inoculation volume was 0.2 ml (containing 50% Matrigel), and the tumor was grown to 200 mm 3 The rats were divided into 4 groups according to the S-shaped grouping based on the tumor size, with 5 rats in each group.

[0649] 2.3. Animal Dosing and Testing

[0650] Tumor-bearing nude mice were administered the drug via tail vein according to the following regimen:

[0651] Table 7. Dosing regimen for NCI-H358 transplant tumor model

[0652] At the end of the experiment, tumor size, photos, and weight were recorded.

[0653] 2.4. Tumor volume and body weight determination:

[0654] Tumor volume and body weight were measured on days 1, 4, 8, 11, 15, 18, 22, 25, and 29 of the experiment, and TGI% was calculated.

[0655] The formula for calculating tumor volume (V) is: V = 1 / 2 × L length × L short 2.

[0656] The TGI calculation formula is TGI (%) = (1-T / C) x 100% (T and C are the relative tumor volumes of the treatment group and the control group, respectively, at a specific time point).

[0657] Experimental results

[0658] Table 8. Effects of multi-bullet ADCs on tumor size in the NCI-H358 xenograft model (tumor volume: mm 3 )

[0659] As shown in Table 8, Figures 2 and 3, the disclosed multi-bullet ADC exhibited a strong in vivo tumor-suppressing effect, with a TGI exceeding 90%, reaching a maximum of 95.80%. Furthermore, during administration, the mice showed no significant weight loss and no other significant toxicity.

[0660] 6. Antibody-drug conjugate (ADC) coupling efficiency test

[0661] During the preparation of B7H3-ADC-001, 0.2 mL of sample was removed after 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours, and excess cysteine ​​was added. The DAR values ​​were then measured. The results (Table 9) show that the DL003 coupling reaction achieved a DAR of 6.0 in approximately 10 minutes, indicating a rapid reaction rate and a near-100% utilization rate. The DL014 coupling reaction was completed in over 2 hours, reaching a DAR of 1.82 and a utilization rate of approximately 91%.

[0662] Table 9. Coupling efficiency of multi-toxin antibody conjugates

[0663] The above-mentioned antibody-drug conjugate efficiency test results show that DL003 is essentially fully coupled after 10 minutes, stabilizes after 30 minutes, and has a utilization rate close to 100%. The other toxin linker stabilizes after 2 hours of coupling. Therefore, the present invention can precisely control the ratio of multiple toxins by controlling the amount of toxin-linker feed to achieve the appropriate toxin-linker ratio.

[0664] 7. Stability testing of antibody-drug conjugates (ADCs)

[0665] Study objectives:

[0666] To simulate ADC cleavage in tumor tissue / tumor microenvironment, the ADC stability was investigated in vitro in nude mouse tumor tissue homogenate, mouse muscle tissue homogenate, homogenate matrix saline, and human, monkey, rat, and mouse plasma. Toxin release was measured in an incubation system. The results from tumor tissue homogenate were compared with those from muscle tissue and plasma to assess the efficiency of toxin release in tumor tissue / tumor microenvironment.

[0667] Experimental steps:

[0668] Homogenize the tissue and dilute with saline for later use. Test the protein concentration in each homogenate, then adjust the concentration to the same level by dilution. Add the prepared ADC dilution to the homogenate or blood and incubate at 37°C. Toxin release is measured at 0, 4, 24, and 48 hours. For details, see Example 6.11 of WO2022170971.

[0669] Results and Discussion

[0670] In terms of toxin molecule release, the ADC of the present invention can release a large amount of toxin molecules in tumor tissue homogenate, but no significant release is observed in normal tissue homogenate or plasma, suggesting that the toxin linker of the ADC of the present invention has the characteristic of tumor tissue-specific toxin release.

[0671] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. The multi-warhead antibody-drug conjugate of formula I, or a stereoisomer, prodrug, pharmaceutically acceptable salt or solvate thereof, in, T is a non-engineered antibody; L1, L2 and L3 are linkers, which covalently bind T and corresponding D1, D2 and D3, and L1, L2 and L3 may be the same or different; D1, D2 and D3 are drug units, and D1, D2 and D3 may be the same or different; and when D1, D2 and D3 are the same, L1, L2 and L3 are different; n1, n2, and n3 are each independently selected from any value between 0 and 8, and when one of n1, n2, and n3 is 0, the other two are not 0; The S atom connected to T is not an additional external sulfur atom, but the -S- formed by the thiol group contained in T after the disulfide bond is opened and connected with the linker.

2. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to claim 1, characterized in that: One or more of the following conditions are met: (1) L1, L2 and L3 are selected from a cleavable linker and a non-cleavable linker; Preferably, L1, L2 and L3 are selected from linkers that can be cleaved in the tumor microenvironment; Wherein, the linker preferably comprises an amino acid residue or a short peptide consisting of 2-10 amino acid residues, and more preferably comprises a dipeptide, a tripeptide or a tetrapeptide; (2) D1, D2 and D3 are each independently selected from microtubule inhibitors, such as MMAE / MMAF and its derivatives, eribulin and its derivatives, maytansine derivatives; topoisomerase inhibitors, such as camptothecin derivatives; drugs that interfere with DNA synthesis, such as dukamycin or calicheamicin and their derivatives; Preferably, D1, D2 and D3 are each independently selected from MMAE / MMAF and its derivatives, eribulin and its derivatives, camptothecin derivatives, dukamycin or calicheamicin and its derivatives; More preferably, D1 is a camptothecin derivative; More preferably, D2 is eribulin and its derivatives, dukamycin or calicheamicin and its derivatives; More preferably, D3 is MMAE / MMAF and its derivatives; (3) T is an anti-Her 2 antibody or an antigen-binding fragment thereof, an anti-H7H3 antibody or an antigen-binding fragment thereof, or an anti-Trop-2 antibody or an antigen-binding fragment thereof, preferably an anti-Her 2 antibody or an antigen-binding fragment thereof; The anti-Her 2 antibody is, for example, trastuzumab or pertuzumab, preferably trastuzumab; The anti-B7H3 antibody is, for example, 1D1, 1D1-01, 2E3, 2E3-02 antibody, enoblituzumab, mirzotamab, omburtamab; The anti-Trop-2 antibody is, for example, Sacituzumab; (4) The S atoms connected to T in Formula I are all derived from disulfide bonds in the antibody; (5) n1 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8; (6) n2 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8; (7) n3 is an integer or decimal selected from 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8.

3. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to claim 2, characterized in that: Meet one or more of the following conditions: (1) The camptothecin derivative is selected from the following structures: Preferably selected from the following structures: (2) The eribulin derivative is selected from the following structures: Preferably (3) The MMAE / MMAF and its derivatives are selected from the following structures: Preferably selected from the following structures: (4) The dukamycin or calicheamicin and its derivatives are selected from the following structures: (5) D1 and D2 are different, n1 and n2 are not 0, and n3 is 0; or D1 and D3 are different, n1 and n3 are not 0, and n2 is 0.

4. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 3, characterized in that: L1, L2 and L3 are each independently selected from the following structures: Wherein, position 1 is connected to the S atom, and position 2 is connected to D1, D2, and D3; R1 and R2 are each independently selected from H, C1-6 alkyl (e.g., methyl, ethyl, propyl), and C3-6 cycloalkyl (e.g., cyclopropyl); preferably, R1 and R2 are both methyl, ethyl, or propyl; Preferably, L1, L2 and L3 are each independently selected from the following structures: Among them, position 1 is connected to the S atom, and position 2 is connected to D1, D2, and D3.

5. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 3, characterized in that: Meet one or more of the following conditions: (1) L1 is Preferably (2) L2 is Preferably (3) L3 is Preferably 6. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 3, characterized in that: Meet one or more of the following conditions: (1)-L1-D1 is selected from the following structural fragments: Preferably selected from the following structural fragments: (2)-L2-D2 is selected from the following structural fragments: (3)-L3-D3 is selected from the following structural fragments: Preferably selected from the following structural fragments:

7. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 6, characterized in that: Meet one or more of the following conditions: (1) n1 and n2 are each independently selected from any value between 1 and 8, and n3 is 0; D1 is a camptothecin derivative; D2 is eribulin and its derivatives; T, L1, L2 are as defined in any one of claims 1 to 6; (2) n1 and n3 are each independently selected from any value between 1 and 8, and n2 is 0; D1 is a camptothecin derivative; D3 is MMAE / MMAF and its derivatives; T, L1, L3 are as defined in any one of claims 1 to 6; (3) n2 and n3 are each independently selected from any value between 1 and 8, and n1 is 0; D2 is MMAE / MMAF and its derivatives; D3 is eribulin and its derivatives; T, L2, L3 are as defined in any one of claims 1 to 6; (4) n1 and n2 are each independently selected from any value between 1 and 8, and n3 is 0; D1 is a camptothecin derivative; D2 is dukamycin or calicheamicin and its derivatives; T, L1, L2 are as defined in any one of claims 1-6.

8. The conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate according to any one of claims 1 to 7, characterized in that: The conjugated drug is selected from:

9. A method for preparing the conjugated drug or its stereoisomer, prodrug, pharmaceutically acceptable salt or solvate as claimed in claim 1, comprising: A coupling reaction is carried out in a suitable solvent with a mixture of antibody T(SH)n with opened interchain disulfide bonds and optionally Lg-L1-D1, Lg-L2-D2, and Lg-L3-D3 in a determined ratio; in: When the linkers of L1, L2, and L3 contain When Lg-L1, Lg-L2, Lg-L3 contain When the linkers of L1, L2, and L3 contain When Lg is a leaving group when reacting with T(SH)n; preferably, Lg is selected from halogen, sulfone, tertiary amine salt (Me3N+, Et3N+), diazonium salt, -OMs, MeSO2-, CF3SO3-; more preferably, Lg is selected from F, MeSO2-; The definitions of L1, D1, L2, D2, L3, D3, n1, n2, n3 are as defined in any one of claims 1 to 10; Preferably, the preparation method satisfies one or more of the following conditions: (1) The coupling reaction is carried out in water and / or an organic solvent; the organic solvent is preferably selected from N,N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, nitriles (such as acetonitrile), alcohols (such as methanol, ethanol) or any combination thereof; (2) The preparation method comprises: conducting a coupling reaction in a suitable solvent with an antibody T(SH)n having an interchain disulfide bond opened and a mixture of Lg-L1-D1 and Lg-L2-D2 in a determined ratio, wherein the determined ratio of Lg-L1-D1 and Lg-L2-D2 is preferably 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5, more preferably 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5; The preparation method preferably comprises: conducting a coupling reaction in a suitable solvent with an antibody T(SH)n having an interchain disulfide bond opened and sequentially or simultaneously adding Lg-L1-D1 and Lg-L2-D2 in a determined ratio; Alternatively, the preparation method comprises: conducting a coupling reaction in a suitable solvent with an antibody T(SH)n having an interchain disulfide bond opened and a mixture of Lg-L1-D1 and Lg-L3-D3 in a determined ratio, wherein the determined ratio of Lg-L1-D1 and Lg-L3-D3 is preferably 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5, more preferably 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 or 7.5; the preparation method preferably comprises: conducting a coupling reaction in a suitable solvent with an antibody T(SH)n having an interchain disulfide bond opened and sequentially or simultaneously adding Lg-L1-D1 and Lg-L3-D3 in a determined ratio.

10. A drug-linker conjugate, or a stereoisomer, prodrug, pharmaceutically acceptable salt or solvate thereof, having the following structure:

11. A pharmaceutical composition comprising the conjugated drug, stereoisomer thereof, prodrug thereof, pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof according to any one of claims 1 to 8, and optionally one or more pharmaceutical excipients.

12. Use of the conjugated drug, stereoisomer thereof, prodrug thereof, pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof as claimed in any one of claims 1 to 8, or the pharmaceutical composition as claimed in claim 11 in the preparation of a drug for treating and / or preventing a disease associated with abnormal cell activity (e.g., cancer disease); Preferably, the cancer disease is a solid tumor and / or a blood tumor; More preferably, the cancer disease is selected from esophageal cancer (e.g. esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (e.g. small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial carcinoma, non-Hodgkin's lymphoma, central nervous system tumor (e.g. glioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer; preferably selected from gastric cancer, non-small cell lung cancer, breast cancer and breast adenocarcinoma; Or the cancer disease is selected from tumors with high HER2 expression or low HER2 expression; the tumor with high HER2 expression is preferably breast adenocarcinoma, and the tumor with low HER2 expression is preferably gastric cancer and / or breast cancer; Or the cancer disease is selected from drug-resistant tumors, and the drug-resistant tumor is preferably selected from esophageal cancer (such as esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (such as small cell lung cancer and non-small cell lung cancer), squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, urothelial carcinoma, non-Hodgkin's lymphoma, central nervous system tumors (such as glioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer or thyroid cancer; preferably, ABCB1 or ABCG2 transporters are overexpressed in the drug-resistant tumor; the drug-resistant tumor is more preferably gastric cancer resistant to Enhertu.

Citation Information

Patent Citations

  • Recombinant immunoglobin preparations

    US4816567A

  • Drug-conjugates with a targeting molecule and two different drugs

    CN106132431A

  • Eribulin-based antibody-drug conjugates and methods of use

    CN108883198A

  • Bioactive substance conjugate and preparation method and application thereof

    CN113683622A

  • Tandem double-drug link assembly unit and application thereof

    CN113941007A

Cited By

  • Eribulin derivative and antibody-drug conjugate thereof, and medical use thereof

    WO2025228172A1

  • Antibody-drug conjugate having linking system

    WO2026092685A1